NEWS 18 MAY 22 CA/CAplus enhanced with IPC reclassification in Japanese patents

NEWS 19 JUN 27 CA/CAplus enhanced with pre-1967 CAS Registry Numbers

NEWS 20 JUN 29 STN Viewer now available

NEWS 21 JUN 29 STN Express, Version 8.2, now available

NEWS 22 JUL 02 LEMBASE coverage updated

NEWS 23 JUL 02 LMEDLINE coverage updated

NEWS 24 JUL 02 SCISEARCH enhanced with complete author names

NEWS 25 JUL 02 CHEMCATS accession numbers revised

NEWS 26 JUL 02 CA/CAplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:55:55 ON 10 JUL 2007

=> file registry
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 09:56:08 ON 10 JUL 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4 DICTIONARY FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10549546b.str

```
chain nodes :
7  8  9  10  12  13  14  22
ring nodes :
1  2  3  4  5  6  11  15  16  17  18
chain bonds :
6-7  7-8  7-13  7-14  8-9  8-22  9-10  10-11  10-12
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  11-15  11-18  15-16  16-17  17-18
exact/norm bonds :
6-7  7-8  7-13  7-14  8-9  8-22  9-10  10-11  10-12  11-15  11-18  15-16  16-17
17-18
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
```

G1:C,N

Match level : 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 22:CLASS

1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

G1 C,N

Structure attributes must be viewed using STN Express query preparation.

20 ANSWERS

=> s 11 SAMPLE SEARCH INITIATED 09:57:14 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 2186 TO ITERATE

91.5% PROCESSED 2000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 40916 TO 46524

PROJECTED ANSWERS: 157 TO 717

L2 20 SEA SSS SAM L1

=> d scan

L2 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

N Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxylacetyl)-4-(6-nitro-3-pyridinyl)- (9CI)

MF C23 H31 N5 07 5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
Piperazine, 1-(1-methyl-4-piperidinyl)-4-[(2-[methyl[(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI)
C21 H31 C13 N4 O4 S . 2 C4 H4 O4

CM 1

Double bond geometry as shown.

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full FULL SEARCH INITIATED 09:57:49 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 43351 TO ITERATE

100.0% PROCESSED 43351 ITERATIONS SEARCH TIME: 00.00.01

369 ANSWERS

L3 369 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

173.00 173.21

FILE 'CAPLUS' ENTERED AT 09:57:54 ON 10 JUL 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jul 2007 VOL 147 ISS 3 FILE LAST UPDATED: 9 Jul 2007 (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13

L4 18 L3

=> d 14 1-18

```
L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:259671 CAPLUS
DN 146:297694
TI Biocompatible cyanine fluorescent imaging agents and method of in vivo optical imaging
IN Rajopadhye, Hilind, Groves, Kevin
PA Visen Hedical, Inc., USA
PCT Int. Appl., 98pp.
COODEN: PIXXD2
DT Patent
LA English
PAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
                                                                                                   NO. KIND DATE APPLICATION NO. DATE

1028163 A1 20070308 W0 2006-US34604 20060901
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, F1, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, II, IN, IS, JP, KE, KG, AW, NN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LV, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NO, N1, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, LA, LG, US, UZ, VC, VW, ZA, ZM, ZW
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, F1, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MG, NL, PL, PT, NO, RS, LS, TT, LU, LV, MG, NL, KP, BY, BY, SY, TJ, TM, TN, TR, TT, TZ, CR, CG, CI, CM, GA, GN, GQ, GW, HL, MR, ME, SN, TD, TG, BW, GH, CM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, ND, RU, TJ, TD, GSD902

ALL-CITATIONS AVAILABLE IN THE RE FORMAT
                                              WO 2007028163
                                                                           RW:
```

```
ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:241640 CAPLUS
DN 142:463562
TI Synthesis of 3-Arylpiperidines by a Radical 1,4-Aryl Migration
AU Gheorghe, Alexandrus Quiclet-Sire, Beatrice; Vila, Xavier, Zard, Samir Z.
CS Laboratoire de Synthese Organique, Departement de Chimie, Ecole
Polytechnique, Palaiseau, 91128, Pr.
SO Organic Letters (2005), 7(8), 1653-1656
CODEN: ORLEFT, ISSN: 1523-7060
PB American Chemical Society
U Journal
LA English
CCASREACT 142:463562
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
                                                                         THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:857596 CAPLUS
DN 141:350198
THETEOCYCLIC (piperazine- and piperidine-containing) benzenesulfonamide derivatives, method for their production, therapsucic compositions, and use thereof for treatment of pain and inflammation
IN Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean-Michel
PA Laboratoires Fournier S.A., Fr.
PCT Int. Appl., 127 pp.
CODEM: PIXXD2
PT Patent
LA French
PAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE
| Face | 
            OS MARPAT 141:350198
RE.CNT 10 THERE AR
                                                                                                                                                                           THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:610647 CAPLUS
DN 145:224314
T Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: hydroxamic acid analogs
AU Gupta, S. P.; Kumaran, S.
CS Department of Chemistry, Birla Institute of Technology and Science, Pilani, 333031, India
SO Medicinal Chemistry (2006), 2(3), 243-250
CODEN: MCERAJ; ISSN: 1573-4064
DB Bentham Science Publishers Ltd.
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN 2004:800854 CAPLUS 141:314016
 L4
AN
DN
TI
           141:314016
Preparation of benzenesulfonamides as Bradykinin Bl receptors antagonists for treatment of pain and inflammation
Barth, Martines Bondoux, Micheli Doddy, Pierres Massardier, Christines Thomas, Didlers Luccarini, Jean Michel
Laboratoires Fournier S.A., Fr.
Fr. Denande, 27 pp.
CODEN: FRXXBL
 IN
CODEN: From.
DT Patent
LA French
FAN.CNT 2
PATENT NO.
                                                                                       APPLICATION NO.
                                                  KIND
                                                                DATE
                                                                                                                                     DATE
         FR 2852958
FR 2852958
AU 2004226197
CA 2519110
WO 2004087700
                                                               20041001
20050624
20041014
20041014
20041014
20041118
                                                                                       FR 2003-3602
                                                                                                                                     20030325
                                                   A1
A1
A1
A1
A2
                                                                                       AU 2004-226197
CA 2004-2519110
WO 2004-FR723
                                                                                                                                     20040324
                                                                                                                                     20040324
WO 2004087700
WO 2004087700
```

```
L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:485895 CAPLUS
DN 139:223711
THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
2004:349769 CAPLUS
141:71820
Synthesis of Cyclic Peptidosulfonamides by Ring-Closing Metathesis
Brouwer, Arwin J., Liskamp, Rob M. J.
Department of Medicinal Chemistry, Utrecht Institute for Pharmaceutical
Sciences, Utrecht University, Utrecht, NL-3508 TB, Neth.
Journal of Organic Chemistry (2004), 69 (11), 3662-3668
CODEN: JOCEAH; ISSN: 0022-3263
American Chemical Society
Journal
English
CASREACT 141:71820
THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:96004 CAPLUS
DN 132:151682
TI Preparation of sulfonylaminoalkanediamides and related compounds as matrix metalloproteinase inhibitors.
IN Beckett, Raymond Paulr Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
PA British Biotech Pharmaceuticals Ltd., UK
SO U.S., 32 pp., Cont.-in-part of Ser. No. Wo97GB-9702891.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 6022873 A 20000208 US 1998-121033 19980723
WO 9817655 Al 19980430 WO 1997-62891 19971020
W: AU, BR, CA, CN, CZ, DE, GB, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US
RV: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE PT 1030842 T 200301201 PT 1997-912351 19971113
PATAI GB 1996-21814 A 19961019
WO 1997-082891 A2 19971020
EF 1997-912351 A 19971113
OS MARPAT 132:151682
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:626184 CAPLUS
DN 131:242793
TI Preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors
IN Beckett, Raymond Pauli Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon
PA British Biotech Pharmaceuticals Limited, UX
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
TP Patent
LA English
FAN.CH 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PATENT NO. BASE ST. TRANSPORTED NO. SG. SK. TR.
RW: AT, BE, CH, DE, DK, ES, FT, FR, GB, GR, IE, IT, UM, CNL, PT, SE
AU 9868435 A 19991018 AU 1998-68435 19980325
PRI AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
JP 200352273 T 20030229 JP 2000-537864 19980325
PRAI WO 1998-68914 A 19980325
PRAI WO 1998-68914 A 19980325
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:662331 CAPLUS
N 132:30315
TI The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors
AU Martin, Fionna M.; Beckett, R. Paul; Bellamy, Claire L.; Courtney, Paul; F.; Davies, Stephen J.; Drummond, Alan H.; Dodd, Rory; Pratt, Lisa M.; Patel, Sanjay R.; Ricketts, Michelle L.; Todd, Richard S.; Tuffnell, Andrew R.; Ward, John W. S.; Whittaker, Mark
CS British Biotech Pharmaceuticals Limited, Oxford, OX4 5LY, UK
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(19), 2887-2892
CODEN: BMCLE8; ISSN: 0960-894X
BE 1sevier Science Ltd.
DT Journal
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

AN	1999:460409 CAPLUS			
DN	131:87805			
TI	Preparation of ampr	enavir prodruge	as HIV protease inhibito	re
IN	Tung, Roger D., Hal	e, Michael R., B	aker, Christopher T.; Fu	rfine, Eric
			Wieslaw Wieczyslaw: Spa	
	Andrew			
PA	Vertex Pharmaceutic	als Incorporated	ties .	
so	PCT Int. Appl., 110		, 05/1	
30	CODEN: PIXXD2	pp.		
DT				
	Patent			
LA	English			
FAN.	CNT 1			
	PATENT NO.	KIND DATE	APPLICATION NO.	DATE

PI,	WO 9933815	A1 19990708	WO 1998-US4595	19980309
	W: AL, AM, AT,	AU, AZ, BA, BB,	BG, BR, BY, CA, CH, CN,	CU, CZ, DE,
	DK, EE, ES,	FI. GB. GE. GH.	GM, GW, HU, ID, IL, IS,	JP. KE. KG.
			LT, LU, LV, MD, MG, MK,	
	NO. NZ. PL.	PT. RO. RU. SD.	SE, SG, SI, SK, SL, TJ,	TM. TR. TT.
		U2, VN, YU, 2W	,,,,,	,,,
			UG, ZW, AT, BE, CH, DE,	DK. RS. FT.
	FD GB GD	IR IT III NO	NL, PT, SE, BF, BJ, CF,	CG CI CM
	CA CN MI	MR, NB, SN, TD,	TC 35, 57, 50, C1,	ca, cr, cm,
	US 6436989	B1 20020820	US 1997-998050	19971224
	AU 9865466	A 19990719		19980309
	AU 755087	B2 20021205	AC 1990-05400	19900309
	AU (/5508 /	B2 20021205	#P 2000 200002615	10000000
	TR 200002615	B2 20021205 T2 20010122 A 20010925 A 20011217 B1 20050415 A2 20020429		19980309
	BR 9814480	A 20010925		19980309
	EE 200000385	A 20011217	EE 2000-385	19980309
	EE 4466	B1 20050415		
	HU 200101831	A2 20020429	HU 2001-1831	19980309
	AP 1172	A 20030630	AP 2000-1850	19980309
	W: GH, GM, KE,	LS, MW, SD, SZ,		
	NZ 505776	A 20030630	NZ 1998-505776	19980309
	CA 2231700	C 19990624	CA 1998-2231700	19980310
	CA 2231700	A1 19990624		
	JP 11209337	A 19990803	JP 1998-58705	19980310
	JP 3736964	B2 20060118		
	EP 933372	A1 19990804		19980310
			GB, GR, IT, LI, LU, NL,	
		LV, FI, RO		,,,
	TW 486474	B 20020511	TW 1998-87121460	19981222
	ZA 9811830	A 20000623		19981223
	IN 1998CA02210	A 20051014		19981223
	NO 2000003304	A 20000821		20000623
		A 20010219		20000623
	US 6559137	B1 20030506		20000623
	BG 104631	A 20010228	BG 2000-104631	200000724
	DC 64960	N 20010228	BG 2000-104631	20000724
	BG 64869 US 2003207871	A 20010228 B1 20060731 A1 20031106 B2 20050104	HC 2002 270171	20020210
	05 2003207871	A1 20031106	US 2003-370171	20030219
	US 6838474	B2 20050104		*****
		A1 20050707	US 2004-958223	20041004
	JP 2005350478	A 20051222	JP 2005-205007	20050713
PRAI	US 1997-998050	A2 19971224		
		¥ 19980309		
	JP 1998-58705	A3 19980310		
	US 2000-602494	A3 20000623		
	US 2003-370171	A3 20030219		
os	MARPAT 131:87805			

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:460392 CAPLUS
D1 31:87803
TI Preparation of 1,3-diacylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors.
IN Hale, Michael R., Tung, Roger D., Baker, Christopher T., Spaltenstein, Andrew; Purfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Mieczyslaw
PA Vertex Pharmaceuticals Incorporated, USA
SP ECT Int. Appl., 109 pp.
CODEM: PIXKD2
D7 Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
FAN.CNT 1
EAL, AM, AT, AJ 19990016 WO 1998-US27403 19981223
WO 9933792 A2 1999016 WO 1998-US27403 19981223
WO 9933792 A3 1999016
W: AL, AM, AT, AJ 19990016
W: AL, AM, AT, AJ 19990016
W: AL, AM, AT, AJ 19990016
W: AL, AM, AT, AJ 19990176
W: AL, AM, NO, NZ, PL, PT, RO, RU, SD, SS, GS, IS, SK, SL, TJ, TH, TT, UA, UG, US, UZ, VN, VU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, RE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9920102
PRAI US 1997-68806F P 19971224
OS MARPAT 131:87803
```

DN TI	131:87804 Preparation of 1,3-discylamino-2-acyloxypropanes as prodrugs of asparty																	
	pro	teas	e in	hibi	tors						••	•		•	•		•	
IN		le, M: irew;																in,
	Hie	czys	l av															
PA		rtex 1					Inco	rpor	ated	, VS	٨							
50		Int DEN: 1			86	pp.												
DΤ		tent												•				
LA		lish																
FAN.	CNT	1																
		ENT I				KIN		DATE				LICAT					ATE	
ΡI	WO	9933	793			A2		1999	0708			1998-					9981	
	WO	9933.				A3		1999										
		w:	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,
												LT,						
			MU.	MX.	NO.	NZ.	Pl.	PT.	RO.	BU.	SD	SE,	SG.	SI.	SK.	SI.	TJ.	TM.
			TR.	TT.	UA.	UG.	US.	UZ.	VN.	YU.	ZW	,	50,	٠.,	٠,	,	,	,
		RW:										AT,	BE.	CH,	CY.	DE,	DK,	ES.
												PT.						
			CM,	GA,	GN,	GW,	ML,	MR,	NE,	SN,	TD.	TG						
	CA	2316	218			A1		1999			CA :	1998-				1	9981	223
		9920				A		1999				1999-					9981	
		9814				۸.		2000	1010		BR :	1998 - 1998 -	1448	4			9981	
	EP	1042															9981	
		R:							FR,	GB,	GR,	IT,	LI,	LU,	NL,	5E,	MC,	PT,
		20000		51,	LT,	tv,						2000-	2000		•		9981	222
		20000				A .			0122 1217			2000-		U24U	۷		9981	
		20011				î		2001				2000-		77			9981	
		2001				Å2		2002				2001-					9981	
		20010				A3		2002				.001-				•	,,,,,	
		1110		•		В		2003			CN :	1998-	8133	13		1	9981	223
		20001		316		Ä		2001				2000-					0000	
	NO	20000	0033	32		A		2000	0818		NO :	2000-	3332			2	0000	626
	IN	20001	KN00	131		Α		2005				-000				2	0000	713
		20000				A1		2001				2000-					0000	
		2002				A1		2002				2001-					0011	
		2003				Al		2003			US 2	2002-	2264	30		2	0020	821
PRAI		1997				P		1997										
		1998				w.		1998										
		2000				Al		2000										
os		RPAT			4	DI		2001	1130									
V 3	- CA				•													
					•								•					

```
L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:410405 CAPLUS
DN 125:86538
TI Imidazopyridine derivatives as dual histamine (H1) and platelet activating factor (PAP) antagonists.
IN Hiller, Andrew Bowles, Stephen Arthur; Ayscough, Andrew Paul; Whittaker, Mark
PA British Biotech Pharmaceuticals Limited, UK
CODEN: PIXXD2
TO PATENT
LA English
FAN.CNT 1
PATENT NO. XIND DATE APPLICATION NO. DATE

PI WO 9605201 Al 19960222 WO 1995-GB1878 19950809
W: AU, CA, CN, CZ, DE, FI, GB, HU, JP, KR, NO, NZ, PL, RU, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9531863 A 19960307 AU 1995-31863 19950809
EP 775139 Al 19970220
FR: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
US 5753671 A 19980519 US 1997-776783 19970210
PRAI GB 1994-16143 A 19940810
GB 1995-5808 A 19950809
OS MARPAT 125:86638
```

L4	ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN	1989:633573 CAPLUS
DN	111:233573
ΤI	Syntheses of $N\alpha$ - $(\beta$ -naphthylsulfonylglycyl)argininamides as potential selective synthetic thrombin inhibitors
AU	Etemad-Moghadam, Guita: Delebassee, Denis: Maffrand, Jean Pierre: Frehel Daniel
CS	Lab. Chim. Coord., Univ. Paul-Sabatier, Toulouse, 31400, Fr.
50	European Journal of Medicinal Chemistry (1988), 23(6), 577-85 CODEN: EJMCA5; ISSN: 0223-5234
DΤ	Journal
LA	English ·
วร	CASREACT 111:233573

L4	ANSWER 17 OF 18 CA	PLUS COPYRIGHT	2007 ACS on STN	
AN	1994:107072 CAPLUS			
DN	120:107072			
TI	4-(1H-2-methylimida	zof4.5-clayridiny	/lmethyl)phenylsulfonami	de derivative
	as antagonists of p			
IN	Whitaker, Mark, Bow			
PA	British Bio-Technol			
50	PCT Int. Appl., 109	pp.		
	CODEN: PIXXD2	••		
DT	. Patent			
LA.	English			
FAN.	CNT 1			
	PATENT NO.	KIND DATE	APPLICATION NO.	DATE
PI	WO 9316075	Al 19930819	WO 1993-GB273	19930210
	W: AU, CA, FI,	JP, KR, NO, NZ,	PT, US	
	RW: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IE, IT, LU, MC,	NL, PT, SE
	AU 9334599	A 19930903	AU 1993-34599	19930210
	AU 662208	B2 19950824	EP 1993-903261	
	EP 635018	A1 19950125	EP 1993-903261	19930210
	EP 635018	B1 19991222		
	R: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IE, IT, LI, LU,	NL, PT, SE
	JP 07503954	T 19950427	JP 1993-513899	19930210
	AT 187966	T 20000115	GB, GR, IE, IT, LI, LU, JP 1993-513899 AT 1993-903261 ES 1993-903261 US 1994-284570	19930210
	ES 2142861	T3 20000501	ES 1993-903261	19930210
				19941027
PRAI	GB 1992-2791	A 19920211		
	WO 1993-GB273	A 19930210	• •	
QS	MARPAT 120:107072			

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:259671 CAPLUS
DOCUMENT NUMBER: 146:297694
Biocompatible cyanine fluorescent imaging agents and method of in vivo optical imaging
Rajopadhye, Milindi Groves, Kevin
Visen Medical, Inc., USA
PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: Patent English

PATENT NO. KIND DATE APPLICATION NO DATE WO 2007028163 W: AE, AG 20070308

imaging) 928031-27-0 CAPLUS INDEX NAME NOT YET ASSIGNED

CM 1

CRN 928031-26-9 CMF C64 H70 N6 016 S5

ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

PAGE 1-B

2 CM

121-44-8 C6 H15 N

928031-35-0 CAPLUS INDEX NAME NOT YET ASSIGNED

СН 1

CRN 928031-34-9 CMF C61 H68 N4 015 S5

ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

CM 2

CRN CMF 121-44-8 C6 H15 N

928031-31-6 CAPLUS INDEX NAME NOT YET ASSIGNED

СМ 1

CRN 928031-30-5 CMF C62 H70 N4 016 S5

ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 121-44-8 CMF C6 H15 N

REFERENCE COUNT: THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:
DOCUMENT NUMBER:
145:224314

AUTHOR(S):
CORPORATE SOURCE:
SOURCE:
PUBLISHER:
DOCUMENT TYPE:
LANGUAGE:
DOCUMENT TYPE:
LANGUAGE:
LANGUAGE:
CORPORATE SOURCE:
DOCUMENT TYPE:
DOCUMENT TYPE:
LANGUAGE:
LANGUAGE:
COPPLISHER:
DOCUMENT TYPE:
LANGUAGE:
LANGUAGE:
COPPLISHER:
DOCUMENT TYPE:
LOURD ACT AND ACT

PUBLISHER: Bentham sussession DOCUMENT TYPE: Journal English
LANGUAGE: Brglish
17 206553-57-3 206553-72-2 244296-01-3
244296-09-1 244296-22-8 244296-25-1
RL: PRC (Pharmacological activity), PRP (Properties), BIOL (Biological activity)

RE: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study) (QSAR studies of hydroxamic acid analogs on matrix metalloproteinase inhibitors) 206553-57-3 CAPLUS 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-mathoxypheny)]sulfonyi]methyljamino]methyl]-β-(2-methylpropyi)-γ-οxo-, (αR, βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

206553-72-2 CAPLUS l-Piperidinebutanamide, α -[[{5-(dimethylamino)-l-naphthalenyl]sulfonyl]methylamino]methyl]-M-hydroxy- β -{2-methylpropyl}- γ -oxo-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) 244296-22-8 CAPLUS 1-Fiperidinebutanamide, $\alpha-\{\{\{\{4-chlorophenyl\} \neq ulfonyl\} methylamino\} methyl]-\beta-(cyclopentylmethyl)-h-hydroxy-y-oxo-, (<math>\alpha R, \beta R)-\{9C1\}$ (CA INDEX NAME)

Absolute stereochemistry.

244296-25-1 CAPLUS

1-Piperidinebutanamide, β -(cyclopentylmethyl)-N-hydroxy- α - [[methyl (1-naphthalenylsulfonyl)amino]methyl]- γ -oxo-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERÊNCE COUNT:

50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

244296-01-3 CAPLUS l-Piperidi nebutanamide, β -{cyclopentylmethyl}-N-hydroxy- α -{{{4-methoxyhenyl} sulfonyl|methyl|amino|methyl}-y-oxo-, { α R, β R}- {9Cl} (CA INDEX NAME)

Absolute stereochemistry.

244296-09-1 CAPLUS 1-Piperidi nebutanamide, β -(cyclopentylmethyl)- α -[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-y-cxo-, (GR, β R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN ACCESSION NUMBER: 2005:241640 CAPLUS DOCUMENT NUMBER: 142:463562

DOCUMENT NUMBER:

142:463562
Synthesis of 3-Arylpiperidines by a Radical 1,4-Aryl Migration Ghoorghe, Alexandru, Quiclet-Sire, Beatrice, Vila, Xavier, Zard, Samir Z.
Laboratoire de Synthese Organique, Departement de Chimie, Ecole Polytechnique, Palaiseau, 91128, Fr. Organic Letters (2005), 7(8), 1653-1656
CODEN: ORLEF7, ISSN: 1523-7060
American Chemical Society
Journal
English

AUTHOR(S):

CORPORATE SOURCE:

SOURCE:

PUBLISHER:

DOCUMENT TYPE: LANGUAGE:

English CASREACT 142:463562 OTHER SOURCE(S):

R SOURCE(S): CASREACT 142:40JD02

851461-08-0p
RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT (Reactant or reagent)
(preparation and radical 1,4-aryl migration reaction of)

851461-08-0 CAPLUS
Carbonodithioic acid, 5-[1-[[acetyl[(4-bromophenyl)sulfonyl]amino]methyl]-4-oxo-4-(1-piperidinyl)butyl) 0-ethyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:
DOCUMENT NUMBER:
11TLE:

111350198
11TLE:

111350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
11141350198
1114130198
1114130198
1114130198
1114130198
11141301

PR

PATENT NO.						KIND DATE				APPI	LICAT		DATE				
								WO 2004-FR723									
WO 2004087700																	
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
											EC,						
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	15,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	Yυ,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	5Z,	TZ,	UG,	ZM,	ZW,	AM,	AZ,
											BG,						
		ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	ΙT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,
					ΒJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	G₩,	ML,	MR,	NE,	SN,
		TD,	TG														
FR .	2852	958			A1		2004	1001		FR 2	2003-	3602			2	0030	325
FR	2852	958			B1		2005	0624									
FR	2853	648			A1		2004	1015		FR 2	2003-	4530			2	0030	411
FR .	2853	648			Bl		2006	0818									
AU .	2004	2261	97		A1		2004	1014		AU 2	2004-	2261	97		2	0040	324
CA	2519	110			A1		2004	1014		CA 2	2004 - 2004 -	2519	110		2	0040	324
EP																	
	R:										IT,						
											TR,						
BR .	2004	0086	19		A		2006	0328		BR 2	2004-	8689			2	0040	324
JP .	2006	5213	33		T		2006	0921		JP 2	2006-	5057	49		2	0040	324
US .	2006	1783	50		A1		2006	0810		US 2	2006- 2005- 2005-	495	46		2	0050	914
NO.	2005	0043	51		٨		2005	1101		NO 2	2005-	4361			. Z	0050	920
KITY	APP	LN.	INFO	. :						FK 4	2003-	1002				0030	325
											2003-				. 2	0030	411

OTHER SOURCE(S): MARPAT 141:350198

1T 766558-09-2P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl]-1-piperaziny]-2-oxosthoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide

RL: PAC (Pharmacological activity), PEP (Physical, engineering or chemical process), PYP (Physical process), RCT (Reactant), SFN (Synthetic preparation); THU (Therapautic use); BIOL (Biological study); PREP (Preparation), PROC (Process); ARCT (Reactant) or reagent), USES (Uses) (drug candidate, resolution) preparation of piperazine- and piperidine-containing

benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-09-2 CAPLUS

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) oxosthoxy|ethyl|benzeneoulfonamide 775286-20-9P, N-[2-[2-[4-(1-Methyl-4-piperidinyl]-1-piperazinyl]-2-oxosthoxy|ethyl]-2,6-dichloro-4-fluoro-N-methylbenzeneoulfonamide 775286-41-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl]-1-piperidinyl]-2-oxosthoxy|ethyl]-4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-Amino-1-piperidinyl])-2-oxosthoxy|ethyl]-4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-[8-methyl-8-azabicyclo]3,2:1]oct-3-yl]amino]-1-piperidinyl]-2-oxosthoxy|ethyl]-benzeneoulfonamide RL: PAC (Pharmacological activity): RCT (Reactant): SPN (Synthetic preparation): THU (Therapeutic use): BIOL (Biological study): PREP (Preparation): RACT (Reactant or reagent): USES (Usea) (drug candidates prepara or preparation-and piperidine-contq. benzeneoulfonamide derivs. sp analgesics and antiinflammatories) 766558-11-6 CAPLUS
Piperazina, 1-[35]-l-azabicyclo{2.2.2}oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]- (SCI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

766558-25-2 CAPLUS
Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

775286-20-9 CAPLUS
Piperazine, 1-[[2-[[(2.6-dichloro-4-fluorophenyl) sulfonyl]methylamino]etho
xylacetyl]-4-(1-methyl-4-piperidinyl)- (SCI) (CA INDEX NAME)

775286-41-4 CAPLUS
Piperidine, 1-[[2-[[{4-methoxy-2,6-dimethylphenyl}]sulfonyl]methylamino]eth

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

766558-14-9P, N-[2-[2-[4-([3R]-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoothoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate
RE: PAC [Pharmacological activity); PUR (Purification or recovery); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperazine- and piperidine-containing benzenesulfonamid derivs. ap analgesics and antiinflammatories)
766558-14-9 CAPLUS
Piperazine, 1-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (ZE)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CRN 766558-13-8 CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (+).

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

 $\label{eq:continuous} 766558-11-6P, N-\{2-\{2-\{4-\{(3S)-1-\lambda zabicyclo\{2,2,2\}oct-3-yl\}-1-piperazinyl\}-2-oxoethoxy\}-thyl\}-4-methoxy-N,2,6-trimethyl-N-\{2-\{2-\{4-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{2-\{4-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{2-\{4-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{2-\{4-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{2-\{4-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{2-\{4-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{2-\{4-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{2-\{4-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{2-\{4-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{2-\{4-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl\}-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl]-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl]-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl]-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl]-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl]-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl]-2-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl]-1-thyl-N-\{1-methyl-4-piperidinyl\}-1-piperazinyl]-1-thyl-N-\{1-methyl-4-methyl-4-piperazinyl]-1-thyl-N-\{1-methyl-4-methyl-4-piperazinyl]-1-thyl-N-\{1-methyl-4-methyl-4-piperazinyl]-1-thyl-N-\{1-methyl-4-methyl-4-piperazinyl]-1-thyl-N-\{1-methyl-4-methyl-4-piperazinyl]-1-thyl-N-\{1-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methy$

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) oxy]acetyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

775287-57-5 CAPLUS
4-Piperidinamie, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylami
nojethoxylacetyl]- (9Cl) (CA INDEX NAME)

775287-58-6 CAPLUS
4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino|sthoxy|scetyl]-N-(8-methyl-8-szabicyclo[3.2.1]oct-3-yl)- (9CI) (CA INDEX NAME)

766558-06-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methy lamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl]ethyl]piperazine bis(trifluoroacetate) 766558-08-1P, N-[2-[2-[4-(1- Azabicyyolo(2,2.2)oct-3-yl)]-1-piperazinyl]-2-oxoethoxy]ethyl]-N, 2, 4, 6-tetramethylbenzenesulfonamide bistrifluoroacetate 766558-10-5P, N-[2-[2-[4-(4-(1-Azabicyyolo(2,2.2)]oct-3-yl)]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N, 2, 6-trimethylbenzenesulfonamide difumarate 766558-12-7P, N-[2-[2-[4-(4-(3)-1-Azabicyolo(2,2.2)]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N, 2, 6-trimethylbenzenesulfonamide fumarate 766558-16-1P, 1-[2-[(4-Methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]piperazine bis(trifluoroacetate) 766558-18-3P, 1-[2-[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylphenylsulfonyl]methylphenylsulfonyl]methylphenylsulfonylmethylphenylp

AMSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2oxosthoxy|sthyl]benzenesulfonanide bis[trif]uoroactate)

766558-28-59, 4-Hethoxy-N, 26-trimethyl-1-[2-[2-[4-[8-Memthyl-8azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxosthoxy]sthyl]benzenesulfona
mide fumarate 76558-30-99, 1-[1-Azabicyclo[2.2.2]oct-3yl)hexahydro-4-[[2-[([4-methoxy-2,6-dimethylphenyl)]sulfonyl]methylamino]st
hoxy]acxtyl]-1H-1,4-diazepine fumarate 775285-46-69,

N-[2-[2-[4-(3-(1-Azetidinyl)]propyl]-1-piperazinyl]-2-oxosthoxy]ethyl]-4methoxy-N,2.6-trimethylbenzenesulfonamide difumarate 775285-46-69,

N-[2-[2-[4-(1-Methyl-3-piperidinyl)]-1-piperazinyl]-2-oxosthoxy]ethyl]-4methoxy-N,2.6-trimethylbenzenesulfonamide difumarate 775285-56-89, N-[2-[2-[4-(1-Methyl-2-imidazolyl]methyl]-1-piperazinyl]-2oxosthoxy]ethyl]-4-methoxy-N,2.6-trimethylbenzenesulfonamide difumarate 375285-56-89, N-[2-[2-[4-(1-Methyl-2-fiperidinyl)-1-piperazinyl]-2oxosthoxy]ethyl]-4-methoxy-N,2.6-trimethylbenzenesulfonamide
difumarate 375285-58-09, N-[2-[2-[4-(3-(inmethylbenzenesulfonamide difumarate 375285-68-89, N-[2-[2-[4-(1-Methyl-3-azabicyclo[3.3.1]non-3-yl)-1-piperazinyl]-2oxosthoxy]ethyl]-4-methoxy-N,2.6-trimethylbenzenesulfonamide difumarate 375285-62-69, N-[2-[2-[4-(3-(1-Pyrrolidinyl)propyl]-1-piperazinyl]-2oxosthoxy]ethyl]-4-methoxy-N-ethyl-2.6-dimethylbenzenesulfonamide difumarate 375285-62-69, N-[2-[2-[4-(3-(1-E-thyl)-1-piperazinyl]-2oxosthoxy]ethyl-4-methoxy-N-ethyl-2.6-dimethylbenzenesulfonamide difumarate 375285-68-29, N-[2-[2-[4-(3-(1-E-thyl)-3-piperazinyl]-2oxosthoxy]ethyl-4-methoxy-N-ethyl-2.6-dimethylbenzenesulfonamide difumarate 375285-69-29, N-[2-[2-[4-(3-(1-E-thyl)-3-miperazinyl]-2oxosthoxy]ethyl-4-methoxy-N-ethyl-2.6-dimethylbenzenesulfonamide difumarate 375285-80-89, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2oxosthoxy]ethyl-4-methoxy-N-ethyl-2-6-dimethylbenzenesulfonamide difumarate 375285-80-89, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2oxosthoxy]ethyl-

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) trimethylbenzenesulfonamide trifluoroscetate 775286-40-3P, N-[2-[2-[4-[2-(0]imethylamino]-1-hydroxyethyl]-1-piperidinyl]-2-oxoethoxylethyl-4-methoxy-N, 2, 6-trimethylbenzeneulfonamide trifluoroscetate 775286-42-5P, 4-Methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperainyl)-1-piperidinyl]-2-oxoethoxylethylbenzenesulfon amide fumarate 775286-44-7P, 4-Methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-(4-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxylethylbenzenesulfon amide fumarate 775286-48-7P, 4-Methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-(4-[1-pyrtolidinyl)+thyl]-1-piperidinyl]-2-oxoethoxylethylbenzenesulfon amide fumarate 775286-56-5P, 4-Methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-[4-[1-methylethyl]-1-piperidinyl]-2-oxoethoxylethylbenzenesulfonamide fumarate 775286-57P, N-Ethyl-4-methoxy-2, 6-dimethyl-N-[2-[2-[4-[2-[1-pyrtolidinyl]-2-oxoethoxylethylbenzenesulfonamide fumarate 775286-57P, N-Ethyl-4-methoxy-2, 6-dimethyl-N-[2-[2-[4-[2-[1-pyrtolidinyl]-2-oxoethoxylethylbenzenesulfonamide fumarate 775286-58-3P, N-Ethyl-4-methoxy-1, 2, 6-trimethyl-N-[2-[2-[4-[2-[methyl]-4-methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-[2-[methyl]-4-methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-[1-[methylethyl]-4-methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-[methyl]-4-methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-[methyl]-4-methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-[methyl]-4-methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-[methyl]-4-methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-[methyl-4-piperidinyl]-2-oxoethoxylethyl]-2-oxoethoxylethylbenzenesulfonamide fumarate 775286-68-5P, 4-Methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-(1-cyclopropyl-4-piperidinyl]-2-oxoethoxylethylbenzenesulfonamide fumarate 775286-68-5P, 4-Methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-(1-cyclopropyl-4-piperidinyl]-2-oxoethoxylethylbenzenesulfonamide fumarate 775286-68-5P, 4-Methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-(1-cyclopropyl-4-piperidinyl]-2-oxoethoxylethylbenzenesulfonamide fumarate 775286-68-5P, 4-Methoxy-N, 2, 6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxylethylbenz

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) dichloro-4-methoxy-N-methylbenzenesulfonamide fumarate 775285-99-99. N-[2-[2-[4-(35)-1-Azabicyclo[2.2.2]oct-3-y1)-1-piperaziny]]-2-oxoethoxy] ethyl]-4-methoxy-N-methyl-2-6 dichlorobenzenesulfonamide fumarate 775286-01-6P.
N-[2-[2-[4-(1,2.2,6.6-Pentamethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy] ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide bis[trifluoroactate] 775286-03-9P, N-[2-[2-[4-[4]-4-Methyl-1-piperazinyl]propyl]-1-piperazinyl]-2-oxoethoxy] ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-03-0P, N-[2-[2-[4-[6-Ethyl-8-azabicyclo]3.2.1]oct-3-y1]-1-piperazinyl]-2-oxoethoxy] ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-03-0P, N-[2-[2-[4-[8-(1-Methylethyl-3-azabicyclo]3.2.1]oct-3-y1]-1-piperazinyl]-2-oxoethoxy] ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-03-0P, N-[2-[2-[4-[8-(1-Methylethyl-3-azabicyclo]3.2.1]oct-3-y1]-1-piperazinyl]-2-oxoethoxy] ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide bis[trifluoroactate] 775286-13-0P, N-[2-[2-[4-[8-(1-Methylethyl-3-azabicyclo]3.2.1]oct-3-y1]-1-piperazinyl]-2-oxoethoxy] ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide bis[trifluoroactate] 775286-13-0P, N-[2-[2-[4-[3-(1-Methylhexhyloroy)]-4-Methoxy-N,2,6-trimethylbenzenesulfonamide bis[trifluoroactate] 775286-13-0P, N-[2-[4-[2-(4-Methylhexhyloro-HI-1,4-diazepin-1-y1]-thyl-1-piperazinyl]-2-oxoethoxy] ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-13-0P, N-[2-[2-[4-(2-(4-Methylhexhyloro-HI-1,4-diazepin-1-y1]-thyl-1-piperazinyl]-2-oxoethoxy] ethyl-1-4-methoxy-N-2,6-dichioro-N-methylbenzenesulfonamide difumarate 775286-13-0P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy] ethyl-1-4-piperidinyl-1-piperazinyl-2-oxoethoxy] ethyl-1-4-piperidinyl-1-piperazinyl-1-2-oxoethoxy] ethyl-1-4-piperidinyl-1-piperazinyl-2-oxoethoxy] ethyl-1-4-piperidinyl-1-piperazinyl-2-oxoethoxy] ethyl-1-4-dichioro-N-methylbenzenesulfonamide 775286-25-4P, N-[2-[2-[4-(1-Methyl-

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) pytrolidiny1] ethyl]-1-piperidiny1]-2-oweethoxy]ethyl] benzenesulfonamide fumarate 775287-00-8P, N-(2-(2-(4-(2-(1)-4-))-4-methoxy)-8, 2-(1)-4-methyl)-1-piperidiny1]-2-oweethoxy]ethyl]-1-piperidiny1]-2-oweethoxy]ethyl]-1-piperidiny1]-2-oweethoxy]ethyl]-4-methyl)-1-piperidiny1]-2-oweethoxy]ethyl]-4-methoxy-N-(2-(2-(4-(2-(1)-4-(1)-4-(2-(1)-4-(1)-4-(2-(1)-4-(1)-4-(2-(1)-4-(1)-4-(2-(1)-4-(1)-4-(2-(1)-4-(1)-4-(2-(1)-4-(1)-4-(2-(1)-4-(1)-4-(2-(1)-4-(1)-4-(2-(1)-4-(1)-4-(1)-4-(2-(1)-4-(1)-

RN 766558-10-5 CAPLUS
Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-y1)-4-[[2-{[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedicate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-09-2 CMF C25 H40 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Cont

PAGE 1-A

PAGE 2-A

- ·

CRN 76-05-1 CMF C2 H F3 O2

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 766558-12-7 CAPLUS
CN Piperazine, 1-(35)-1-azabicyclo[2.2.2]oct-3-y1-4-{[2-[(4-methoxy-2,6-dimethylphenyl] sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (SCI) (CA INDEX NAME)

CM 1

CRN 766558-11-6 CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (-).

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown

RN 766558-16-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxylacetyl]-4-[3-(1-pyrrolidinyl)propyl]-, bis(trifluoroacetate) (9Cl)
(CA INDEX NAME)

CM 1

CRN 766558-15-0 CMF C25 H42 N4 O5 S PAGE 1-A

PAGE 2-A

CM 2

CRN 76-05-1 CMF C2 H F3 O2

 $\label{eq:continuous} \begin{array}{lll} \textbf{766558-18-3} & \textbf{CAPLUS} \\ \textbf{Piperazine,} & \textbf{1-\{\{2-\{\{4-methoxy-2,6-dimethylphenyl\} \text{ sulfonyl}\} \text{methylamino}\} \text{eth} \\ \end{array}$

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)

PAGE 1-B

2 CM

CRN 76-05-1 CMF C2 H F3 O2

F-C-CO2H

766558-22-9 CAPLUS Piperazine, 1-[[2-[[4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth oxy]acetyl]-4-[3-(1-piperidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-21-8 CMF C26 H44 N4 O5 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

F- C- CO2H

766558-24-1 CAPLUS
1-Fiperazinepropanamine, 4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-N,N-dimethyl-,bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) oxylacetyl]-4-[2-(4-morpholinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CAINDEX NAME)

CM 1

CRN 766558-17-2 CMF C24 H40 N4 O6 S

PAGE 1-B

2 СН

CRN 76-05-1 CMF C2 H F3 O2

766558-20-7 CAPLUS Piperazina, 1-{[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth cxy|acetyl-4-{2-(1-piperidinyl]ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-19-4 CMF C25 H42 N4 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 76-05-1 CMF C2 H F3 Q2

766558-26-3 CAPLUS Piperazine, 1-[[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(1-methyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN · 766558-25-2 CMF C24 H40 N4 O5 S

2 CM

CRN. 76-05-1 CMF C2 H F3 O2

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
766558-28-5 CAPLUS
Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxyl_acetyl]-4-[8-methyl-8-azabicyclo[3.2.1]oct-3-yl}-, (2E)-2-butenedioate
(1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 766558-27-4 CMF C26 H42 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

766558-30-9 CAPLUS IN-1,4-Diazepine, 1-(1-azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[{4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) [9CI] (CA INDEX NAME)

CM 1

CRN 766558-29-6 CMF C26 H42 N4 O5 S

Double bond geometry as shown.

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN CMF C4 H4 O4 (Continued)

Double bond geometry as shown.

775285-54-6 CAPLUS Piperazine, 1-{[2-{[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-{[(1-methyl-1H-imidazol-2-yl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-53-5 CMF C23 H35 N5 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-56-8 CAPLUS
Piperazine, 1-[[2-[ethyl](4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho
kylacetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9C1)
(CA INDEX NAME)

CM 1

CRN 775285-55-7 CMF C25 H42 N4 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

775285-46-6 CAPLUS ,
Piperazine, 1-[3-(1-azetidinyl)propyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedicate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-45-5 CMF C24 H40 N4 O5 S

СН 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-48-8 CAPLUS
Piperazine, 1-[[2-[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth
oxy]acetyl]-4-(1-methyl-3-piperidinyl)-, (2E)-2-butenedicate (1:2) (9C1)
(CA INDEX NAME)

CM 1

CRN 775285-47-7 CMF C24 H40 N4 O5 S

CM

CRN 110-17-8

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

CRN 110-17-8 CMF C4 H4 Q4

Double bond geometry as shown.

775285-58-0 CAPLUS
1-Piperazinepropanamine, 4-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl]sulfonyl]amino]ethoxy]acstyl]-N,N-dimethyl-,(2E)-2-butenedioste (1:2) (9C1) (CA INDEX NAME)

CRN 775285-57-9 CMF C24 H42 N4 O5 S

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-60-4 CAPLUS Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth oxy]acety]-4-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-59-1 CMF C27 H44 N4 O5 S

СМ 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-62-6 CAPLUS
Piperazine, 1-[[2-[ethyl[{4-methoxy-2,6-dimethylphenyl]sulfonyl]amino]etho
xy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI)
(CA INDEX NAME)

CRN 775285-61-5 CMF C26 H44 N4 O5 S

PAGE 1-A

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007-ACS on STN (Continued) ky|acetyl]-4-(8-methyl-8-azabicyclo{3.2.1|oct-3-yl}-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CRN 775285-67-1 CMF C27 H44 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-72-8 CAPLUS
Piperazine, 1-(1-cyclopropyl-4-piperidinyl)-4-{[2-{{4-methoxy-2,6-dimethylphenyl} sulfonyl]methylamino]ethoxy|acetyl]-, (2E)-2-butenedicate
{1:2) (9C1) (CA INDEX NAME)

CM 1

CRN 775285-71-7 CMF C26 H42 N4 05 S

СМ

Double bond geometry as shown.

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-66-0 CAPLUS
Piperazine, 1-(8-cyclopropyl-8-azabicyclo[3.2.1]oct-3-y1)-4-{{2-{{4-methody-2,6-dimethylphenyl}sulfonyl]methylamino|ethoxylacetyl]-, (2E)-2-butenedioate (1:1) {9C1} (CA INDEX NAME)

CM. 1

CRN 775285-65-9 CMF C28 H44 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 Q4

Double bond geometry as shown.

775285-68-2 CAPLUS Piperazine, 1-{{2-{ethyl{(4-methoxy-2,6-dimethylphenyl)sulfonyl}amino}etho

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

775285-74-0 CAPLUS
Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl][(1-methylathy)]amino]ethoxy]acetyl]-4-[8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedicate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-73-9 CMF C28 H46 N4 O5 S

$$\begin{array}{c|c} & & & & & & & & & & \\ & & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\ &$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-76-2 CAPLUS
Piperazine, 1-{1-ethyl-4-piperidinyl}-4-{{2-{{4-methoxy-2,6-dimethylphenyl}sulfonyl]methylamino}ethoxylacetyl}-, {2E}-2-butenedioate {1:1} (9CI) (CA INDEX NAME)

CM 1

CRN 775285-75-1 CMF C25 H42 N4 O5 S

2 CM

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

© CO2H

775285-78-4 CAPLUS
Piperazine, 1-[1-(1,1-dimethylethyl)-4-piperidinyl]-4-[[2-[[4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-77-3 CMF C27 H46 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-80-8 CAPLUS Piperazine, 1-{[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino|ethoxylacetyl]-4-{(1-methyl-4-piperidinyl)methyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-79-5 CMF C25 H42 N4 O5 S

2

CRN 110-17-8 CMF C4 H4 O4

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN CRN 110-17-8 CMF C4 H4 O4 (Continued)

Double bond geometry as shown.

775285-85-3 CAPLUS
Piperazine, 1-{[2-[{(4-methoxy-2,6-dimethylphenyl}sulfonyl}methylamino]eth
oxy]acetyl]-4-{[(1-methyl-4-piperidinyl)methyl}-, (2E)-2-butenedioate (1:2)
(SCI) (CA INDEX NAME)

CM 1

CRN 775285-79-5 CMF C25 H42 N4 O5 S

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-87-5 CAPLUS IH-1,4-Diazepine, hexahydro-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-4-(l-methyl-4-piperidinyl)-, (2E)-2-butenedicate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-86-4 CMF C25 H42 N4 O5 S

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

Double bond geometry as shown.

€ со₂н

775285-82-0 CAPLUS
1-Piperazinepropanamine, 4-[{2-[{2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino|ethoxy|acetyl}-N,N-dimethyl-,(ZE)-2-butenedioate {!:2} (9Cl) (CA INDEX NAME)

CRN 775285-81-9 CMF C21 H34 C12 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

 $\label{eq:continuous} \raiset{ 775285-84-2 CAPLUS Piperazine, 1-[[2-[\{2,6-dichloro-4-methoxyphenyl]sulfonyl]methylamino]ethoxy]acetyl]-4-[1-methyl-4-piperidinyl]-, (2E)-2-butenedicate (1:2) (9CI) (CA INDEX NAME) } \end{subarray}$

CM 1

CRN 775285-83-1 CMF C22 H34 C12 N4 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN CM $\,$ 2

Double bond geometry as shown.

775285-89-7 CAPLUS
Piperazine, 1-[[2-[[4-methoxy-2,6-dimethylphenyl]sulfonyl][1-methylethyl]amino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl]-,
(ZE)-2-butenedioate [1:2] (9C1) (CA INDEX NAME)

CM 1

CRN 775285-88-6 CMF C26 H44 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-91-1 CAPLUS
Piperazine, 1-[[2-[[4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth
oxy]acety]-4-[1-(1-methylethyl)-4-piperidinyl]-, (2E)-2-butenedicate
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-90-0 CMF C26 H44 N4 O5 S

Double bond geometry as shown.

775285-93-3 CAPLUS
Piperazine, 1-[[2-[ethyl][(4-methoxy-2,6-dimethylphenyl]sulfonyl]amino]ethoxyl]acetyl]-4-[3-(1-piperidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-92-2 CMF C27 H46 N4 O5 S

2 CM

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-95-5 CAPLUS
Piperazine, 1-[[2-[[(2,4-dichloro-6-methoxyphenyl)sulfonyl]methylamino]ethoxy]acety]]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-94-4 CMF C22 H34 C12 N4 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 775285-98-8 CMF C23 H34 C12 N4 O5 S

Absolute stereochemistry.

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-01-6 CAPLUS Piperazine, 1-{[2-{{(4-methoxy-2,6-dimethylphenyl)sulfonyl}methylamino]ethoxy]acetyl}-4-{1,2,2,6,6-pentamethyl-4-piperidinyl}-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-00-5 CMF C28 H48 N4 O5 S

2

CRN 76-05-1 CMF C2 H F3 O2

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-97-7 CAPLUS Piperazine, $1-[2-[\{(2,6-\text{dichloro-}4-\text{methoxyphenyl}\}\text{sulfonyl}]\text{methylamino}]$ eth oxy]acety] $-4-\{1-\text{ethyl-}4-\text{piperidinyl}\}-, (2E)-2-\text{butenedicate} \{1:1\}$ (9CI) (CA INDEX NAME)

1 CM

CRN 775285-96-6 CMF C23 H36 C12 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown

775285-99-9 CAPLUS
Piperazine, 1-(35)-1-azabicyclo(2.2.2)oct-3-yl-4-([2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl}-, (2E)-2-butenedioate (iii) (9CI) (CA INDEX NAME)

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

775286-03-8 CAPLUS Piperazine, 1-{[2-{[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino}eth oxy|acetyl]4-{[3-(4-methyl-1-piperazinyl)propyl]-, (2E}-2-butenedioate (1:2) (9Cl) (CA INDEX NAME)

CH 1

CRN 775286-02-7 CMF C26 H45 N5 O5 S

PAGE 1-B

__ OMe

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-05-0 CAPLUS
Piperazine, 1-(8-ethyl-8-azabicyclo[3.2.1]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-04-9 CMF C27 H44 N4 O5 S

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-07-2 CAPLUS
Piperazine, 1-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl)-4-[{2-[(4-methyxy-2,6-dimethylphenyl)sulfonyl)methylamino]ethoxylacetyl}-,
(2E)-2-butenedicate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-06-1 CMF C27 H47 N5 O5 S

PAGE 1-B

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

PAGE 1-B

CM 2

CRN 76-05-1 CMF C2 H F3 O2

F-C-CO2H

775286-13-0 CAPLUS
Piperazine, 1-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-4-{[2[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl}-,
[2E]-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CH 1

CRN 775286-12-9 CMF C26 H45 N5 O5 S

PAGE 1-A

PAGE 1-B

CRN 110-17-8 CMF C4 H4 O4

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

© CO2H HO2C

775286-09-4 CAPLUS
Piperazine, 1-{[2-[[(4-methoxy-2,6-dimethylphenyl)gulfonyl]methylamino]ethoxy]acety]]-4-{8-(1-methylethyl)-8-azabicyclo[3.2.1]cct-3-yl]-,
(2B)-2-butenedioate (1:2) (9C1) (CA INDEX NAME)

CH 1

CRN 775286-08-3 CMF C28 H46 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-11-8 CAPLUS IH-1,4-Diazepine, hexahydro-1-[3-(4-[{2-[{(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino|ethoxy|acetyl]-1-piperazinyl]-1-oxopropyl]-4-methyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CRN 775286-10-7 CMF C27 H45 N5 O6 S

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN Double bond geometry as shown. (Continued)

775286-17-4 CAPLUS
Piperazine, 1-{35}-1-azabicyclo(2.2.2]oct-3-yl-4-[[2-[ethyl](4-methoxy-2,6-dimethylphenyl)sulfonyl]smino]ethoxy]acetyl)-, (2E)-2-butenedioate (1:2)
(SCI) (CA INDEX NAME)

CM 1

CRN 775286-16-3 CMF C26 H42 N4 O5 S

Absolute stereochemistry. Rotation (-).

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-19-6 CAPLUS
1-Piperazineethanamine, N,N-diethyl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-, (2E)-2-butenedicate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-18-5 CMF C24 H42 N4 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

CM 1

CRN 775286-20-9 CMF C21 H31 C12 F N4 O4 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-22-1 CAPLUS
Piperazine, 1-[[2-[[(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino]ethox
y|acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

775286-23-2 CAPLUS
Piperazine, 1-[[2-[{(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino]ethox
y]acetyl}-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI)

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-26-5 CAPLUS
Piperazine, 1-[(2-{{(2,4-dichloro-6-methylphenyl)sulfonyl]methylamino}etho
xy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

775286-27-6 CAPLUS Piperazine, 1-[[2-[[(2,4-dichloro-6-methylphenyi)sulfonyl]methylamino]etho xylacetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedicate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-26-5 CMF C22 H34 C12 N4 O4 S

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-28-7 CAPLUS
Piperazine, 1-{{2-[[(4-methoxy-2,3,6-trimethylphenyi)sulfonyl]methylamino]
ethoxy]acetyl]-4-{1-methyl-4-piperidinyl}- (9CI) (CA INDEX NAME)

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (CA INDEX NAME) (Continued)

CM 1

CRN 775286-22-1 CMF C21 H31 Br C12 N4 O4 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

ble bond geometry as shown.

775286-24-3 CAPLUS
Piperazine, 1-(1-methyl-4-piperidinyl)-4-([2-[methyl([2,4,6-trichlorophenyl)sulfonyl]amino]ethoxylacetyl]- (SCI) (CA INDEX NAME)

775286-25-4 CAPLUS
Piperazine, 1-{1-methyl-4-piperidinyl}-4-[[2-[methyl[[2,4,6-trichlorophenyl]sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2)
(9C1) (CA INDEX NAME)

CM 1

CRN 775286-24-3 CMF C21 H31 C13 N4 O4 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

775286-29-8 CAPLUS
Piperazine, 1-[[2-[[(4-methoxy-2,3,6-trimethylphenyl]sulfonyl]methylamino]
ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedicate (1:2)
(SCI) (CA INDEX NAME)

CRN 775286-28-7 CMF C25 H42 N4 O5 S

Double bond geometry as shown.

775286-30-1 CAPLUS
Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-4-[3-(4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

775286-31-2 CAPLUS
Piperazine, 1-[[2-[{(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino|ethoxy|acetyl]-4-[3-(1-methyl-4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-B

_ OMe

775286-32-3 CAPLUS
Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acety]-4-[3-(1-methyl-4-piperidinyl)propyl]-, (2E)-2-butenedioate
(1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-31-2 CMF C27 H46 N4 O5 S

PAGE 1-A

PAGE 1-B

__ OMe

СМ 2

Double bond geometry as shown.

© CO2H HO2C

775286-34-5 CAPLUS
Piperazine, 1-[(2-[{(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino|ethoxy|acetyl]-4-(4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

но2с Е со2н

775286-38-9 CAPLUS
4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N,B,B-tetramethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-37-8 CMF C25 H43 N3 O5 S

СМ 2

CRN 76-05-1 CMF C2 H F3 O2

F- C- CO2H

775286-40-3 CAPLUS
4-Piperidinemethanol, a-[(dimethylamino)methyl]-1-{{2-[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-,
mono(trifluoroacetate) (salt) (SCI) (CA INDEX NAME)

CM 1

CRN 775286-39-0 CMF C23 H39 N3 O6 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN CM 1 (Continued)

775286-33-4 C23 H38 N4 O5 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

775286-35-6 CAPLUS
Piperazine, 1-(6-amino-3-pyridinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]- (9CI) (CA INDEX NAME)

775286-36-7 CAPLUS
Piperazine, l-{6-amino-3-pyridinyl}-4-[[2-{[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1 CRN 775286-35-6 CMF C23 H33 N5 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CPA 2

CRN 76-05-1 CMF C2 H F3 02

775286-42-5 CAPLUS Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acatyl]-4-[4-methyl-1-piperazinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-41-4 CMF C24 H40 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

HO2C E CO2H

CRN 775286-43-6 CMF C25 H41 N3 O5 S

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-40-1 CAPLUS
Piperidine, 1-[[2-[[4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth
oxy|acety]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 775286-47-0 CMF C25 H41 N3 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) oxy]acetyl]-4-[4-{1-methylethyl}-1-piperazinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-49-2 CMF C26 H44 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-52-7 CAPLUS
Piperidine, 1-{[2-{ethyl{(4-methoxy-2,6-dimethylphenyl)sulfonyl}amino]etho
xy|acetyl|-4-{2-{(1-pyrrolldinyl)ethyl}-, (2E)-2-butenedioate (1:1) (9Cl)
(CA INDEX NAME)

CM 1

CRN 775286-51-6 CMF C26 H43 N3 O5 S

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued) PAGE 1-A

PAGE 2-A

CM 2

Double bond geometry as shown.

775286-50-5 CAPLUS Piperidine, 1-{{2-{{(4-methoxy-2,6-dimethylphenyl)sulfonyl}methylamino}eth

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)

PAGE 1-A

PAGE 2-A

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-56-1 CAPLUS
Piperidine, 4-{2-{hexahydro-4-methyl-1H-1,4-diazepin-1-yl}ethyl}-1-[[2-

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) {((4-methoxy-2,6-dimethylphenyl)sulfonyl)methylamino|ethoxy|acetyl}-, {2E)-2-butenedioate (1:2) {9Cl} (CA INDEX NAME)

CM 1

CRN 775286-55-0 CMF C27 H46 N4 O5 S

PAGE 1-B

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-58-3 CAPLUS
4-Piperidineethanamine, 1-[{2-[{(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino|ethoxy|acetyl]-N-methyl-N-(1-methylethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-57-2 CMF C25 H43 N3 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-64-1 CAPLUS 4,4'-Bipiperidine, 1-ethyl-1'-[{2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-, (2E)-2-butenedicate (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 775286-63-0 CMF C26 H43 N3 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-66-3 CAPLUS 4.4'-Bipiperidine, 1-cyclopropyl-1'-{{2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-, (2E)-2-butenedicate (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 775286-65-2

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

CM 2

Double bond geometry as shown.

775286-60-7 CAPLUS
4-Piperidinamine, 1-[{2-{i.(4-methoxy-2,6-dimethylphenyl)sulfonyl}methylaminolethoxy]acetyl}-N-methyl-N-(1-methyl-4-piperidinyl)-,
(2E)-2-butenedioate (1:1) (9C1) (CA INDEX NAME)

CM

CRN 775286-59-4 CMF C26 H44 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-62-9 CAPLUS 4.4'-Bipsperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylam ino]ethoxylacetyl]-1'-[1-methylethyl]-, (2E)-2-butenedioate (1:1) {9CI} (CA INDEX NAME)

CRN 775286-61-8 CMF C27 H45 N3 O5 S

(Continued)

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN CMF C27 H43 N3 05 5

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-68-5 CAPLUS
Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth
oxy]acetyl]-4-[2-(4-morpholinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

OH 1

CRN 775286-67-4 CMF C25 H41 N3 O6 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-70-9 CAPLUS Piperidine, $4-\{2-\{1-azetidiny1\}-1,1-dimethylethyl\}-1-[\{2-\{[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)$

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 775286-69-6 CMF C26 H43 N3 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-72-1 CAPLUS
4.4'-Bipiperidine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxylacetyl]-''-methyl-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-71-0 CMF C26 H43 N3 O5 S

CM 2

Double bond geometry as shown.

775286-74-3 CAPLUS

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

775286-80-1 CAPLUS
Piperidine, 4-[2-(1-azetidinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dinethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-79-8 CMF C24 H39 N3 O5 S

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-82-3 CAPLUS
4-Piperidineethanamine, 1-[[2-[[(2,6-dichloro-4-methoxypheny]) sulfony]]methylamino]ethoxy]acetyl]-N,N-dimethyl-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-81-2 CMF C21 H33 C12 N3 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Piperidine, 4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-{[2-{((4-methoxy-2,6-diaethylpheny)] sulfonyl]methylamino|ethoxylacetyl}-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-73-2 CMF C25 H42 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-78-7 CAPLUS 4.4'-Bipiperidine, $1-[\{2-\{\{(2,4-dichloro-3-methylphenyl\}sulfonyl\}methylamino|ethoxy|acetyl\}-1'-methyl-, (2E)-2-butenedicate (1:1) (9CI) (CA INDEX NAME)$

CM 1

CRN 775286-77-6 CMF C23 H35 C12 N3 O4 S

CH 2

CRN 110-17-8 CMF C4 H4 Q4

Double bond geometry as shown.

775286-84-5 CAPLUS 4.4'-Bipiperidine, 1-[[2-[[(2.6-dichloro-4-methoxyphenyl)sulfonyl]methylam ino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) [9CI] (CA INDEX NAME)

CM 1

CRN 775286-83-4 CMF C23 H35 C12 N3 O5 S

CM 2

Double bond geometry as shown.

775286-86-7 CAPLUS
Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth
oxy]acetyl]-4-(1-pyrrolidinylmethyl)-, (2E)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CH 1

CRN 775286-85-6 CMF C24 H39 N3 O5 S

PAGE 2-A

2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-88-9 CAPLUS
Piperidine, 4-[(4-ethyl-1-piperazinyl)methyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl)methylamino]ethoxylacetyl]-, (2E)-2-butenedicate (1:1) (9CI) (CA INDEX NAME)

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) oxy)acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedicate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-93-6 CMF C23 H36 C12 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

 $\label{eq:continuous} \begin{tabular}{lll} 775286-96-9 & CAPLUS & Piperidinyl, ethyl] -1-[{\dot 2}-{\{(4-methoxy-2,6-dinethylpheyl)\} sulfonyl]methylamino]ethoxy]acetyl}--, \\ mono(trifluoroacetate) & (9CI) & (CA INDEX NAME) & (CA I$

CM 1

CRN 775286-95-8 CMF C28 H47 N3 O5 S

2 CM

CRN 76-05-1 CMF C2 H F3 02

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

CM 1

CRN 775286-87-8 CMF C26 H44 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-92-5 CAPLUS Piperidine, 1-[[2-[ethyl](4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxylacetyll-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CH 1

CRN 775286-91-4 CMF C26 H44 N4 O5 5

CP4 2

Double bond geometry as shown.

775286-94-7 CAPLUS
Piperidine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl]sulfonyl]methylamino]eth

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

775286-98-1 CAPLUS
Piperidine, 4-[1,1-dimethyl-2-(1-pyrrolldinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethyl)henyl]mulfonyl]methylamino|ethoxy|acetyl]-,
(2E)-2-butenedioate (1:1) {9CI} (CA INDEX NAME)

CM 1

CRN 775286-97-0 CMF C27 H45 N3 O5 S

PAGE 1-A

(Continued)

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-00-8 CAPLUS
4-Piperidineethanamine, N-ethyl-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino[ethoxy]acetyl]-N-methyl-,
[2E]-2-butenedicate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-99-2 CMF C24 H41 N3 O5 S

Double bond geometry as shown.

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A

CP4 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-06-4 CAPLUS
Piperidine, 4-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

E CO2H HO₂C

775287-02-0 CAPLUS
4-Piperidineethanamine, N,N-diethyl-1-{{2-{((4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy}acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

(Continued)

CH 1

CRN 775287-01-9 CMF C25 H43 N3 O5 S

Double bond geometry as shown.

775287-04-2 CAPLUS
Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino|ethoxy|acetyl|-4-[2-(1-pyrrolidinyl)ethyl]-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CRN 775287-03-1 CMF C27 H45 N3 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) dimethylphenyl) sulfonyl] methylamino[ethoxy]acetyl]-, (2E)-2-butenedicate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-05-3 CMF C27 H45 N3 O6 S

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-08-6 CAPLUS
Piperidine, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1-[{2-[[(4-methyyl-6,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-,
(2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CRN 775287-07-5 CMF C26 H44 N4 O5 S

PAGE 1-B

_ OMe

CM 2

CRN 110-17-8

775287-10-0 CAPLUS
Piperidine, 1-[[2-[{(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-[2-(1-methyl-4-piperidinyl)ethyl]-, (2E)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

CRN 775287-09-7 CMF C27 H45 N3 O5 S

PAGE 1-B

_ OMe

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-12-2 CAPLUS
Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-[1-piperidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-11-1 CMF C26 H43 N3 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

PAGE 2-A

(Continued)

CH 2

F- C- CO2H

775287-16-6 CAPLUS
Piperazine, 1-[1-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]sethoxy]acetyl]-4-piperidinyl]acetyl]-4-methyl-, (2E)-2-butenedicate (1:1) (SCI) (CA INDEX NAME)

CM 1

CRN 775287-15-5 CMF C26 H42 N4 O6 S

PAGE 1-B

-- OMe

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

СМ 2

CRN 110-17-8 CMF C4 H4 Q4

Double bond geometry as shown.

775287-14-4 CAPLUS
Piperidine, 1-[[2-[[[4-methoxy-2-[trifluoromethyl]phenyl]sulfonyl]methylam
ino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, mono(trifluoroacetate)
(SCI) (CA INDEX NAME)

CM 1

CRN 775287-13-3 CMF C24 H36 F3 N3 O5 S

PAGE 1-A

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-18-8 CAPLUS
4-Piperidinemethanamine, l-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy[acetyl]-N,N-dimethyl-,
(28)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CRN 775287-17-7 CMF C22 H37 N3 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-20-2 CAPLUS
Piperidine, 4-(1-azetidinylmethyl)-1-[{2-[{(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl}-, (2E)-2-butenedicate
(1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 775287-19-9 CMF C23 H37 N3 O5 S

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-22-4 CAPLUS 4,4'-Bipiperidine, l-methyl-1'-{[2-{methyl[{2,4,6-trimethylphenyl]+ulfonyl]amino]ethoxy]acetyl}-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-21-3 CMF C25 H41 N3 O4 S

CH 2

CRN 76-05-1 CMF C2 H F3 O2

775287-24-6 CAPLUS 4,4'-Bipiperidine, l-methyl-1'-[[2-[methyl][2-(trifluoromethyl)phenyl]sulfonyllamino]ethoxylacetyl}-,mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-23-5 CMF C23 H34 F3 N3 O4 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) tyl]-4-[2-(1-pyrrolidinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-27-9 CMF C25 H41 N3 O4 S

PAGE 1-A

PAGE 2-A

, CM 2

CRN 76-05-1 CMF C2 H F3 O2

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 76-05-1 CMF C2 H F3 O2

775287-26-8 CAPLUS 4.4'-Bipiperidine, $1-\{\{2-\{\{\{4-methoxy-2-\{trifluoromethyl\}phenyl\}sulfonyl\}methylanglethoxy\}acetyl\}-1'-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)$

CM 1

CRN 775287-25-7 CMF C24 H36 F3 N3 O5 S

CH 2

775287-28-0 CAPLUS
Piperidine, 1-[[2-[methyl](2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]ace

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

775287-30-4 CAPLUS Piperidine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl]sulfonyl]methylamino]eth oxy]acetyl]-4-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-29-1 CMF C22 H34 C12 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-32-6 CAPLUS
4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl).sulfony]]methylamino]ethoxy]acetyl]-N,N-dimethyl-,(2E)-2-butenedicate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-31-5 CMF C23 H39 N3 O5 S

CM 2

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-34-8 CAPLUS
Piperidine, 4-(4-cyclopropyl-1-piperazinyl)-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-, (2E)-2-butenedicate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-33-7 CMF C26 H42 N4 O5 S

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-36-0 CAPLUS
Piperidine, 4-[4-(1,1-dimethylethyl)-1-piperazinyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-, (2E)-2-butenedioate (1:2) (9Cl) (CA INDEX NAME)

CRN 775287-35-9 CMF C27 H46 N4 O5 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-41-7 CAPLUS
Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxylacetyl]-4-[3-(4-morpholinyl)propyl]- (9C1) (CA INDEX NAME)

 $\label{eq:capacity} \begin{tabular}{llll} $775287-42-8 & CAPLUS \\ Piperidine, $1-\{[2-\{(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]^4-\{3-(4-morpholinyl)propyl]^-, $(2E)-2-butenedicate (1:1) $(9CI) $(CA INDEX NAME)$ \\ \end{tabular}$

CM 1

CRN 775287-41-7 CMF C26 H43 N3 O6 S

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-38-2 CAPLUS
Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)oulfonyl]methylamino]eth
oxylacetyl-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2)
(9Cl) (CA INDEX NAME)

CM 1

CRN 775287-37-1 CMF C25 H42 N4 O5 S

CM 2

Double bond geometry as shown.

775287-40-6 CAPLUS
Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth
oxy]acety]-4-[2-(4-methyl-1-piperazinyl)ethyl]-, (2E)-2-butenedioate
(1:2) (9CI) (CA INDEX NAME)

CRN 775287-39-3 CMF C26 H44 N4 O5 S

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-43-9 CAPLUS
Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]- [9CI) (CA INDEX NAME)

PAGE 1-A

RN 775287-44-0 CAPLUS

Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxylgactyl]-4-[3-(1-pyrrolidinyl)propyl]-, (2E)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 775287-43-9 . CMF C26 H43 N3 O5 S

PAGE 1-A

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) CMF C28 H48 N4 O5 S

PAGE 1-B

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 775287-47-3 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxylocetyl]-4-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-B

_ OMe

RN 775287-48-4 CAPLUS Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxylacety|]-4-[3-(4-methyl-1-piperazinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 775287-45-1 CAPLUS
Piperidine, 4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-[[2[{4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]- (9C1)
(CA INDEX NAME)

PAGE 1-B

RN 775287-46-2 CAPLUS
CN Piperidine, 4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-[{2-{(14-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-, (2B)-2-butendioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-45-1

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 775287-47-3 CMF C27 H46 N4 O5 S

PAGE 1-B

__ OMe

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 775287-49-5 CAPLUS
CN Piperidine, 4-[3-(1-azetidinyl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9Ci) (CA INDEX NAME)

RN 775287-50-8 CAPLUS
CN Piperidine, 4-[3-(1-azetidiny1)propy1]-1-[{2-[{(4-methoxy-2,6-dimethylphenyl}sulfony1]methylamino]ethoxy]acety1]-, (2E)-2-butenedioste (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-49-5 CMF C25 H41 N3 O5 S

2 CM

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-51-9 CAPLUS
4-Piperidinepropanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-(CA INDEX NAME)
,

775287-52-0 CAPLUS
4-Piperidinepropanamine, 1-{{2-{{4-methoxy-2,6-dimethylphenyl}oulfonyl}methylamino|ethoxy|acetyl]-N,N-dimethyl-,(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-51-9 CMF C24 H41 N3 O5 S

CRN 110-17-8 CMF C4 H4 O4

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN CMF C22 H37 N3 O5 S (Continued)

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-59-7 CAPLUS

775287-59-7 CAPLUS
4-Piperidinamine, 1-[{2-[{(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino|ethoxy|acetyl}-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-,
bis(trifluoroacetate) (9C1) (CA INDEX NAME)

CM 1

CRN 775287-58-6 CMF C27 H44 N4 O5 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

775287-60-0 CAPLUS
4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyi)sulfonyi]methylaminojethoxyjacetyi]-N-methyl- (9C1) (CA INDEX NAME)

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN Double bond geometry as shown. (Continued)

775287-54-2 CAPLUS 4,4'-Bipiperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylam ino]ethoxyl]ocetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-53-1 CMF C24 H39 N3 O5 S

СМ 2

CRN 76-05-1 CMF C2 H F3 O2

775287-55-3 CAPLUS
4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxylacetyl]-N-methyl- (9CI) (CA INDEX NAME)

775287-56-4 CAPLUS
4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-,
(2E)-2-butenedioate (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 775287-55-3

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

775287-61-1 CAPLUS
4-Fiperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylami
no]sthoxy]acatyl]-N-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)- (9CI)
(CA INDEX NAME)

775287-62-2 CAPLUS
4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylaminojethoxylacetyl]-M-methyl-M-[8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-, bis(trifluoroacetate) [9CI] (CA INDEX NAME)

CM 1

CRN 775287-61-1 CMF C28 H46 N4 O5 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

775287-63-3 CAPLUS
Piperidine, 1-[[2-{[(4-methoxy-2,6-dimethylphenyl}sulfonyl]methylamino}eth
oxy]acetyl]-4-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)

 $\label{eq:continuous} \begin{tabular}{llll} 775287-64-4 & CAPLUS \\ Piperidine, & 1-[\{2-[\{(4-methoxy-2,6-dimethylphenyl\}sulfonyl\}methylamino]ethoxy]acetyl]-4-(1-piperazinylmethyl]-, & (2E)-2-butenedioate & (1:1) & (9CI) & (CAIMDEX NAME) \\ \end{tabular}$

1 CM

CRN 775287-63-3 CMF C24 H40 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

uble bond geometry as shown

775287-66-6 CAPLUS
Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth
oxy]acetyl]-4-[(4-methyl-1-piperazinyl)acetyl]-, bis(trifluoroacetate)
(9C1) (CA INDEX NAME)

CRN 775287-65-5 CMF C26 H42 N4 O6 S

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN CRN 110-17-8 CMF C4 H4 O4 (Continued)

Double bond geometry as shown.

775288-89-6 CAPLUS
4-Piperidineethanamine, N,N-diethyl-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-β,β-dimethyl-monottrifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775288-88-5 CMF C27 H47 N3 O5 S

2

CRN 76-05-1 CMF C2 H F3 O2

775288-66-9P, 4-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methy lamino|ethoxylacetyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester 775288-67-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-(1-piperazinyl)ethoxylethyl]benzenesulfonamide 775288-65-2P, 4-[3-[(4-([2-[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-1-piperazinyl]propyl]-1-piperacinyl]methylamino]ethoxylacetyl]-1-piperazinyl]propyl]-1-piperacinyl]-1-piperazinyl]-1-piperidinecarboxylic acid phenylsulfonyl]methylamino]ethoxylacetyl]-1-piperazinyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 775288-73-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(6-nitro-3-pyridinyl)-1-piperazinyl]ethoxylethyl]benzenesulfonamide 775288-74-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(3-nitro-3-pyridinyl)-1-piperazinyl]ethoxylethyl]benzenesulfonamide 775288-74-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(3-nitro-3-pyridinyl)-2-oxoethoxy]ethyl]benzenesulfonamide 775288-76-IP, 1'-[[2-[(4-Methoxy-2,6-

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

CH 2

CRN 76-05-1 CMF C2 H F3 O2

775287-67-7 CAPLUS
Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acatyl]-4-{1-methyl-4-piperidinyl}-, dihydrochloride (SCI) (CA INDEX
NAME)

775287-68-8 CAPLUS
Piperazine, 1-{[2-{{(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylaminojeth
oxy]acetyl]-4-{[1-methyl-4-piperidinyl]-, (2E)-2-butenedioate (1:2) (9CI)
(CA INDEX NAME)

CRN 766558-25-2 CMF C24 H40 N4 O5 S

CM 2

ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
dimethylphenyl) sulfonyl]methylaminolethoxylacetyl]-4, 4'-bipiperidine1carboxylic acid 1, 1-dimethylathyl ester 775288-77-2P,
[2-[1-[[2-[[(4-Methoxy-2,6-dimethylphenyl]sulfonyl]methylaminolethoxy]acet
yl]-4-piperidinyl]ethyl]methyl[archamic acid 1,1-dimethylethyl ester
775288-78-3P, [1-[[2-[[(4-Methoxy-2,6dimethylphenyl]sulfonyl]methylaminolethoxylacetyl]-4-piperidinyl]carbamic
acid 1,1-dimethylphenyl]sulfonyl]methylaminolethoxylacetyl]-4-piperidinyl]carbamic
acid 1,1-dimethylphenyl]sulfonyl]methylaminolethoxylacetyl]-4-piperidinyl]methylcarbamic acid 1,1-dimethylethyl ester
775288-29-P, 4-[[1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylaminolethoxylacetyl]-4-piperidinyl]methylcacid phenylmethyl ester
775288-83-0P,
1-[[2-[[(4-Methoxy-2,6-dimethylphenyl]sulfonyl]methylaminolethoxylacetyl]-4-piperidinecarboxylic acid estyl ester
775288-83-0P,
1-[[2-[(4-Methoxy-2,6-dimethylphenyl]sulfonyl]methylaminolethoxylacetyl]-4-piperidinecarboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; prepn. of piperazine- and piperidine-contg.
benzenesulfonamide derivs. as analgesics and antiinflammatories)
775288-66-9 CAPLUS
1-Piperazinecarboxylic acid, 4-[[2-[[(4-methoxy-2,6dimethylphenyl]sulfonyl]methylaminolethoxylacetyl]-, 1,1-dimethylethyl
ester (9C1) (CA INDEX NAME)

775288-67-0 CAPLUS
Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxylacetyll- (9C1) (CA INDEX NAME)

775288-69-2 CAPLUS
1-Piperidinecarboxylic acid, 4-[3-[4-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]propyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A

PAGE 1-B

RN 775288-70-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-1-piperazinyl}-,
1,1-dimethylethyl ester (9Cl) (CA INDEX NAME)

RN 775288-73-8 CAPLUS
CN Piperazine, 1-{[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(6-nitro-3-pyridinyl)- (9CI) (CA INDEX NAME)

RN 775288-74-9 CAPLUS
CN 4-Piperidinepropanol, 1-[[2-([(4-methoxy-2,6-dimethylphenyl)sulfonyl]methy laminojethoxy]acetyl]- (9Cl) (CA INDEX NAME)

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

- OBu- t

RN 775288-78-3 CAPLUS
CN Carbamic acid, [1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino jethoxy]acetyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 775288-79-4 CAPLUS
Carbamic acid, [1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino | ethoxy]acetyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 775288-82-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[{1-{[2-{[{4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl}-4-piperidinyl]methyl-, phenylmethyl ester (9Cl) (CA INDEX NAME)

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 775288-75-0 CAPLUS
CN 4-Piperidinepropanol, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino|ethoxylacetyl]-, 4-methylbenzenesulfonate (ester) (9C1) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

RN 775288-76-1 CAPLUS

(A,4'-Bipiperidine)-1-carboxylic acid, 1'-[[2-[[(4-methoxy-2,6-dimethylphenyl)] sulfonyl]methylamino]ethoxylacetyl]-, 1,1-dimethylethylester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & &$$

RN 775288-77-2 CAPLUS
CArbamic acid, [2-[1-[2-[{(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylam ino]ethoxy|acety].4-piperidinyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

RN 775288-83-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-, ethyl ester (9CI)
(CA INDEX NAME)

RN 775288-84-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]bulfonyl]methylamino]ethoxy]acetyl]- [9C1] (CA INDEX NAME)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
SSION NUMBER: 2004:800854 CAPLUS
MENT NUMBER: 141:314016
ACCESSION NUMBER:
                                              Preparation of benzenesulfonamides as Bradykinin Bl
receptors antagonists for treatment of pain and
inflammation
DOCUMENT NUMBER:
TITLE:
                                              inriammation
Barth, Martine; Bondoux, Michel; Dodey, Pierre;
Massardier, Christine; Thomas, Didier; Luccarini, Jean
INVENTOR(S):
                                              Michel
Laboratoires Fournier S.A., Fr.
Fr. Demande, 27 pp.
CODEN: FRXXBL
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
                                              Patent
```

DOCUMENT TYPE: LANGUAGE:						ent																	
	LANGUAGE:	Fre	nch																				
	FAMILY ACC	. NUM.	COU	NT:	2																		
	PATENT INF	ORMATI	ON:																				
	PATEN	T NO.		•	KIN	D	DATE			APP	LICAT	ION	NO.		D.	ATE							
	FR 28	52958			A1		2004	1001		FR	2003-	3602			2	20030325							
	FR 28	52958			В1		2005	0624															
	AU 20	042261	97		A1		2004	1014		ΑU	2004 -	20030323											
	CA 25	19110			A1		2004	1014		CA	2004 -		20040324										
	WO 20	040877	00		Al		2004	1014		WO	2004 -	FR72	3		20040324 BZ, CA, CH,								
	WO 20	040877	A9		2004	1118																	
										BB	, BG,	BR.	BW.	BY.	BZ,	CA,	CH,						
		CN.	CO.	CR.	CU.	CZ.	DE.	DK.	DM.	DZ	EC.	EE,	EG.	ES.	FI.	GB,	GD,						
		GE.	GH.	GM.	HR.	HU.	ID.	IL.	IN.	15	, JP,	KE,	KG.	KP.	KR.	KZ.	LC.						
		LK,	LR,	LS,	LT.	LU,	LV,	MA,	MD,	MG	, MK,	MN,	MW.	MX,	MZ,	NA,	NI,						
		NO.	NZ.	OM.	PG.	PH.	PL.	PT.	RO,	RU	, SC,	SD,	SE,	SG,	SK,	SL,	SY,						
		TJ,	TH.	TN.	TR.	TT.	TZ.	UA.	UG,	US	. UZ.	VC,	VN,	YU.	ZA,	ZM,	ZW						
	P	W: BW.	GH.	GM,	KE,	LS.	MW.	MZ.	SD,	SL	, sz,	TZ.	UG,	ZM.	ZW,	AM.	AZ,						
		BY.	KG.	KZ.	MD.	RU.	TJ.	TM.	AT.	BE	, BG,	CH,	CY,	cz.	DE.	DK.	EE.						
											MC,												
		SK.	TR.	BF.	BJ.	CF.	CG.	CI.	CM.	GA	, GN,	GO.	GW.	ML.	MR.	NE.	SN.						
		TD.	TG		-			-															
	EP 16	06288			A1		2005	1221		EP	2004-	7423	33		2	0040	324						
	P	: AT,	BE.	CH.	DE,	DK,	ES.	FR,	GB,	GR	. IT.	LI,	LU,	NL,	SE,	MC.	PT,						
		IE.	SI.	LT.	LV.	FI.	RO.	MK.	CY,	AL	TR,	BG,	CZ,	EE.	HU,	PL.	SK						
	BR 20	040086	PR		A		2006	0328		BR	2004 -	9689			2	0040	324						
	CN 17	64661	-		A		2006	0426		CN	2004-	8000	7762		2	0040	324						
	JP 20	065213	33		т		2006	0921		JP	2006-	5057	49		2	0040	324						
CN 1764661 JP 2006521333 NO 2005004361 PRIORITY APPLN. INFO.:					À		2005	1101		NO	2005-	4361			2	0050	920						
	PRIORITY A	. :						FR	2003-	3602			A 2	0030	325								
PRIORITI APPEN. INFO.:										FR	2003-	4530			A 2	0030	411						

OTHER SOURCE(s):

MARPAT 141:314016

T766558-09-2P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-y1)-1-piperazinyl]-2-coxecthoxyl-brokensis and inflammation)
RN 766558-09-2P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-y1)-1-piperazinyl]-2-coxecthoxyl-brival-methoxy-N-methyl]-2,6-dimethylbenzenesulfonamide
RL: PAC (Pharmacological activity), PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(Bradykinin Bl receptor antagonist; preparation of benzenesulfonamides as Bradykinin Bl receptor antagonists for treatment of pain and inflammation)
RN 766558-09-2 CAPLUS
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-y1)-4-[[2-[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxylacetyl]- (9CI) (CA INDEX NAME)

ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
]-4-[3-(dimethylamino)propyl]piperazine bistrifluoroacetate
766558-26-3P, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidimyl]-1-piperazinyl]-2-oxoethoxy|ethyl]benzenesulfonamide
bistrifluoroacetate 766558-28-5P, 4-Methoxy-N-methyl-2,6dimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo]3,2.1]oct-3-yl)-1-piperazinyl]2-oxoethoxy|ethyl]benzenesulfonamide fumarate 766558-30-3P
RI: PAC (Pharmacological activity), SPN (Synthetic preparation), THU
(Therapeutic use), BIOL (Biological study), PREP (Preparation), USES
(Uses) (Continued)

(Uses)
(Bradykinin Bl receptor antagonists preph. of benzenesulfonamides as Bradykinin Bl receptor antagonists for treatment of pain and inflammation)
766558-06-9 CAPLUS
Piperazine, 1-{{2-{{(4-methoxy-2,6-dimethylphenyl)sulfonyl}methylamino}eth oxy|acetyl]-4-{2-{1-pyrrolidinyl}ethyl}-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1 CRN 766558-05-8 CMF C24 H40 N4 O5 S

PAGE 1-A

ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

766558-11-6P, N-[2-[2-[4-{(3S)-1-Azabicyclo[2.2.2]oct-3-y1]-1-piperaziny]]-2-oxosthoxy|sthyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide
RL: PAC (Pharmacological activity), PUR (Purification or recovery), RCT
(Reactant); SYN (Synthetic preparation), THU (Therapeutic use), BIOL
(Biological study), PREP (Preparation), RACT (Reactant or reagent), USES ees) (Bradykinin B1 receptor antagonist; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and

oracykini bi teospot analysis inflammation)
766558-11-6 CAPUS
Piperazine, 1-(35)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

766558-06-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl] (meth yl)amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]piperazine bistrifluoroacetate 766558-08-1P, N-[2-[2-[4-(1-Azabicyclo[2,2]otcl-3-yl)-1-piperazinyl]-2-oxoathoxy]ethyl]-N-methyl-2,4,6-trimethylbenzenesulfonamide bistrifluoroacetate 766558-10-5P, N-[2-[2-[4-(1-Azabicyclo[2,2]otcl-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide difumarate 766558-12-7P, N-[2-[2-[4-(138]-1-Azabicyclo[2,2]otcl-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide fumarate 766558-14-9P, N-[2-[2-[4-(13R)-1-Azabicyclo[2,2.2]otcl-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide fumarate 766558-16-1P, 1-[[2-[(4-Methoxy-2,6-dimethylphenyl]sulfonyl] methyl)amino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl)piperazine bistrifluoroacetate 766558-18-3P, 1-[2-{[(4-Methoxy-2,6-dimethylphenyl]sulfonyl]}methyl)amino]ethoxy]acetyl]-4-[3-(1-piperidinyl)ethylpiperazine bistrifluoroacetate 766558-20-7P, 1-[2-[(4-Methoxy-2,6-dimethylphenyl)sulfonyl] (methyl)amino]ethoxy]acetyl]-4-[3-(1-piperidinyl)ethylpiperazine bistrifluoroacetate 766558-24-1P, 1-[[2-[(4-Methoxy-2,6-dimethylphenyl)sulfonyl)giperazine bistrifluoroacetate 766558-24-1P, 1-[[2-[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylphenyl)sulfonyl)giperazine bistrifluoroacetate 766558-24-1P, 1-[[2-[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylphenyl)sulfonyl)giperazine bistrifluoroacetate 766558-24-1P, 1-[[2-[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylphenyl)sulfonyl]methylphenylsulfonyllmethylphenylsulfonyllmethylphenylsulfonyllmethylphenylsulfonyllmethylphenylsulfonyllmethylphenylsulfonyllmethylphenylsulfonyllmethylphenylsulfonyllmethylphenylsulfonyllmethylphenyllmenyllmethylphenyllmenyllmethylphenyllmenyllmenyllmenyllmethylphenyllme

ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

2 CM 76-05-1 C2 H F3 O2

F- C- CO2H

766558-08-1 CAPLUS
Piperazine, 1-{1-azabicyclo[2.2.2]oct-3-y1}-4-[[2-[methyl](2,4,6-trimethylphenyl]oulfonyl]amino]ethoxy]acetyl]-, bis(trifluoroacetate)
(SCI) (CA INDEX NAME)

CM 1

766558-07-0 C25 H40 N4 O4 S

2 СН

CRN 76-05-1 CMF C2 H F3 O2

766558-10-5 CAPLUS
Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-, (2E)-2-butenedicate (1:2) (9C1) (CA INDEX NAME)

CH 1

CRN 766558-09-2 CMF C25 H40 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

766558-12-7 CAPLUS
Piperazine, 1-(35)-1-azabicyclo[2.2.2]oct-3-yl-4-[{2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-, (2E)-2-butenedioate(l:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-11-6 CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (-).

ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

766558-16-1 CAPLUS Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth oxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

СМ 1

CRN 766558-15-0 CMF C25 H42 N4 O5 S

PAGE 1-A

PAGE 2-A

2 .

CRN 76-05-1 CMF C2 H F3 O2

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

766558-14-9 CAPLUS Piperazine, 1- $\{3R\}$ -1-azabicyclo $\{2.2.2\}$ oct-3-yl-4- $\{\{2-\{\{(4-methoxy-2,6-dinethy)|phony\}\}$ oulfonyl]methylamino $\}$ ethoxylacetyl]-, $\{2E\}$ -2-butenedioate $\{1:1\}$ (9CI) (CA INDEX NAME)

CH 1

CRN 766558-13-8 CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (+).

CM 2

Double bond geometry as shown.

ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

766558-18-3 CAPLUS Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth oxy]acetyl]-4-[2-(4-morpholinyl)ethyl]-, bis(trifluoroacetate) [9CI] (CA INDEX NAME)

CM 1

CRN 766558-17-2 CMF C24 H40 N4 O6 S

PAGE 1-B

СМ 2

CRN 76-05-1 CMF C2 H F3 O2

766558-20-7 CAPLUS Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth oxy]acatyl-4-{[2-(1-piperidinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CRN 766558-19-4 CMF C25 H42 N4 O5 S

PAGE 1-B

-- OM o

2 CM

CRN 76-05-1 CMF C2 H F3 O2

F- Ċ- CO2H

766558-22-9 CAPLUS
Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth
oxy]acetyl]-4-[3-(1-piperidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1

CRN 766558-21-8 CMF C26 H44 N4 O5 S

CM 2

CRN 76-05-1 CMF C2 H F3 02

ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

со2н

766558-28-5 CAPLUS Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth oxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:1) [9CI] (CA INDEX NAME)

CM 1

CRN 766558-27-4 CMF C26 H42 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

766558-30-9 CAPLUS IH-1, 4-Diazepine, 1-(1-azabicyclo[2.2.2]oct-3-y1)hexahydro-4-[[2-[[(4-methoxy-2.6-dimethylphenyl]oulfonyl]methylaminolethoxy]acetyl]-, (ZE)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CRN 766558-29-6 CMF C26 H42 N4 O5 S

ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

766558-24-1 CAPLUS
1-Piperazinepropanamine, 4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino|ethoxy]acetyl]-N,N-dimethyl-,bis(trifluoroacetate) [9CI) (CA INDEX NAME)

CM 1

CRN 766558-23-0 CMF C23 H40 N4 O5 S

2 CM

CRN 76-05-1 CMF C2 H F3 02

766558-26-3 CAPLUS Piperazine, 1-[(2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy)acetyl]-4-(1-methyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2 CMF C24 H40 N4 O5 S

ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

766558-13-8P, N-[2-[2-[4-[(3R)-1-Azabicyclo[2,2,2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy] thyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide
RL: PUR (Purification or recovery), RCT (Reactant), PREP (Preparation);
RACT (Reactant or reagent)
(preparation of benzenesulfonamides as Bradykinin Bl receptor antagonists for treatment of pain and inflammation)
766558-13-8 CAPLUS
Piperazine, 1-(3R)-1-azabicyclo[2,2,2]oct-3-yl-4-[{2-[((4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:345769 CAPLUS
TITLE: Synthesis of Cyclic Peptidosulfonamides by Ring-Closing Matathesis
Brouwer, Arwin J. Liskamp, Rob M. J.
Department of Medicinal Chemistry, Utrecht Institute for Pharmacoutical Sciences, Utrecht University, Utrecht, NL-3508 TB, Neth.
JOURNEL SOURCE: ODEN: JOCEAH; ISSN: 0022-3263
American Chemistry (2004), 69(11), 3662-3668
CODEN: JOCEAH; ISSN: 0022-3263
American Chemistry (2004)
American Chemistry (2004)
English

DOCUMENT TYPE: Journal
LANGUAGE: English
CASREACT 141:71820

IT 710300-63-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent
(Reactant of cyclic peptidosulfonamides by ring-closing metathesis)
RN 710300-63-3 CAPLUS
CN Piperidine, 1-[25]-4-methyl-2-[[[25]-3-methyl-2-[[2nitrophenyl]sulfonyl]-2-propenylamino|butyl]sulfonyl]-2-propenylamino]-1oxopentyl]- (SCI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

279254-97-6 CAPLUS l-Piperazinepentanamide, $\alpha-[(1,3-benzodioxol-5-ylmethyl)](4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-8-oxo-4-phenyl-, (aR) - (9CI) (CA INDEX NAME)$

279255-03-7 CAPLUS
1-Piperazinepentanamide, 4-acetyl-α-{{1,3-benzodioxol-5-ylmethyl}{(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino}-N-hydroxy-δ-οxο-,
(αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2003:485695 CAPLUS DOCUMENT NUMBER: 139:223711
TITLE: Noval iahla

AUTHOR (S):

139:223711
Novel Inhibitors of procollagen C-Proteinase. Part 2:
glutamic acid hydroxamates
Robinson, L. A. Vilson, D. M., Delaet, N. G. J.,
Bradley, E. K., Dankwardt, S. M., Campbell, J. A.,
Martin, R. L., Van Wart, H. E., Walker, K. A. M.,
Sullivan, R. W.
CombiChem Inc., San Diego, CA, 92121, USA
Bioorganic 4 Medicinal Chemistry Letters (2003),
13(14), 2391-2384
CODEN: BMCLES, ISSN: 0960-894X
Flavoir Science R.V.

CORPORATE SOURCE: SOURCE:

Elsevier Science B.V.

(Uses)
(preparation and structure-activity relationship of glutamic acid hydroxamates as novel inhibitors of procollagen C-Proteinase)
279254-86-3 CAPLUS
1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl) [(4-methoxy-2,3.6-trimathylphenyl)] uslfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, phenylmethyl ester (9Cl) (CA INDEX NAME)

Absolute stereochemistry.

279254-91-0 CAPLUS

2/9224-91-0 CAPLUS
1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxy-2,3,6-trimethylphenyl]sulfonyl]aminol-5-(hydroxyamino)-1,5-dioxopencyl]-, ethyl ester [9C1] (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

279255-56-0 CAPLUS
1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl)sulfonyl]amino]-4-benzoyl-N-hydroxy-5-oxo-, (αR)- (9CI) (CA INDEX NAME)

RN 591766-09-5 CAPLUS
CN 1-Piperidinepentanamide, α-[{1,3-benzodioxol-5-ylmethyl}][{4-methoxyphenyl} sulfonyl] mino]-N-hydroxy-δ-oxo-4-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-10-8 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)](4-methoxyphenyl) = ulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-11-9 CAPLUS
CN 1-Piperazinepentanamide, α-[{1,3-benzodioxol-5-ylmethyl}[(4-methoxyphenyl)sulfonyl]amino|-N-hydroxy-4-methyl-8-oxo-, {aR}-(9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) methoxyphenyl)sulfonyl]amino]-N-hydroxy-8-oxo-4-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-15-3 CAPLUS
CN 1-Piperazinepentanamide, $\alpha = \{(1,3-benzodioxol-5-ylmethyl)\}\{(4-methoxyhenyl) = ulfonyl|amino|-N-hydroxy-5-oxo-4-(2-pyridinylmethyl)-, {\alpha R} - (9Cl) (CA INDEX NAME)$

Absolute stereochemistry.

RN 591766-16-4 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl) sulfonyl]amino]-N-hydroxy-δ-oxo-4-(3-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-17-5 CAPLUS
CN 1-Piperazinepentanamide, q-[(1,3-benzodioxol-5-ylmethyl)[(4-

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

RN 591766-12-0 CAPLUS
CN 1-Piperazinepentanamide, a-{ (1,3-benzodioxol-5-ylmethyl) { (4-methoxyphenyl) sulfonyl amino} -N-hydroxy-8-oxo-4-phenyl-, (aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-13-1 CAPLUS
CN 1-Piperazinepentanamide, a-[(1,3-benzodioxol-5-ylmethyl)]((4-methoxyphenyl)aulfonyl]amino]-N-hydroxy-8-oxo-4-(2-pyridinyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-14-2 CAPLUS
CN 1-Piperazinepentanamide, a-[(1,3-benzodioxol-5-ylmethyl)][(4-

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) methoxyphenyl) sulfonyl] amino]-N-hydroxy-5-oxo-4-(4-pyridinylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-18-6 CAPLUS
1-Piperazinepentanamide, 4-acetyl- α -{(1,3-benzodioxol-5-ylmethyl)}{(4-methoxyphenyl)sulfonyl]smino]-N-hydroxy-8-oxo-, (α R) - {9Cl} (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-19-7 CAPLUS
CN 1-Piperazinepentanamide, α-[{1,3-benzodioxol-5-ylmethyl}][(4-methoxyphenyl) sulfonyl) amino]-N-hydroxy-4-(methylsulfonyl)-δ-οxο-, (αR)- (SCI) (CA INDEX NAME)

Absolute stereochemistry

RN 591766-20-0 CAPLUS

ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
1-Fiperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethy1)[(4-methoxyphenyl)aufionyl]amino)-5-(hydroxyamino)-1,5-dioxopentyl]-, ethylester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

591766-21-1 CAPLUS
1-Piperazinecarboxylic acid, 4-{ (4R)-4-{ (1,3-benzodioxol-5-ylmethyl) { (4-methoxyhenyl) sulfonyl]amino) -5- (hydroxyamino) -1,5-dioxopentyl] -, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

 $\label{eq:continuous} \begin{array}{lll} 591766-22-2 & CAPLUS \\ 1-Piperazinepentanamide, & & & & & & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)] & (4-methoxyphenyl) & amino]-N-hydroxy-4-[[(4-methoxyphenyl) amino] & amino]-N-hydroxy-4-[[(4-methoxyphenyl) amino] & amino] & - & & & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)] & (2-methoxyphenyl) & amino] & - & & & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)] & (2-methoxyphenyl) & - & & & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)] & (2-methoxyphenyl) & - & & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)] & (2-methoxyphenyl) & - & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)] & - & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)] & (2-methoxyphenyl) & - & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)] & - & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)] & (2-methoxyphenyl) & - & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)] & - & \\ \alpha-[(1,3-benzodioxol-5-ylmethyl)]$

Absolute stereochemistry.

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:
DOCUMENT NUMBER:
133:74324
Preparation of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase.
Billedeau, Roland Joseph, Broka, Chris Allen;
Campbell, Jeffrey Allen; Chen, Jian Jeffrey;
Dankwardt, Sharon Marie; Delaet, Nancy; Robinson,
Leslie Ann; Walker, Keith Adrian Murray
FATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
PT Int. Appl., 133 pp.
CODEN: PIXXD2
Patent

DOCUMENT TYPE:

Patent English

FAMILY ACC. NUM. COUNT:

PATENT NO. WO 2000037436)	DATE			APP	LICAT	ION	NO.		D	ATE	
2000	10374	36		A1	•	2000	0620		wo	1000-	PD00	20			0001	214
										, BR,						
•.	UE,	UR,	MO,	PC.	AU,	CB	GD,	GP,	CU	, GM,	DI,	UII	tn,	CN,	CU,	12,
										LS,						
										. RU.						
										ZA.			Ju,	31,	JA,	36,
RW:													DF	~u	cv	חער
										, MC.						
										. SN.			36,	DF,	ы,	CF,
2355	1902	٠.,	٠.,,	A 1	٠,	2000	0629	••••	~A~	1999-	2355	902		,	9991	214
9916	5504			Α.		2001	0911		BR	1999-	1650	4		i	9991	214
2355 9916 1149	1072			A1		2001	1031		EP	1999-	9635	กัก		i	9991	214
1149	072			R1		2004	0630				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	-		•		~.,
R:	AT.	BE.	CH.	DE.	DK.	ES.	FR.	GB.	GR	, IT,	LI.	LU.	NL.	SE.	MC.	PT.
	IE.	SI.	LT.	LV.	FI.	RO	,	,				,	,	,	,	,
2001	0186	8 .	,	T2	,	2001	1121		TR	2001-	2001	01866	9	1	9991	214
2001	0465	8		A2		2002	0629		HU	2001-	4658			1	9991	214
2002	5333	22		T		2002	1008		JP .	2000-	5895	08		1	9991	214
2001 2002 7693 5122 2702 2232 6492 2001 2001 2001 2001 2003	119			B2		2004	0122		AU .	2000-	1979	2		1	9991	214
5122	92			A		2004	0326	•	NZ	1999-	5122	92 -		1	9991	214
2702	71			T		2004	0715		ΑT	1999-	9635	30		1	9991	214
2232	751			C2		2004	0720		RU .	2001-	1194	61		1	9991	214
6492	394			В1		2002	1210		US	1999-	4696	60		1	9991	222
. 2001	0004	43		A1		2002	0630		HR .	2001-	443			2	0010	614
. 2001	.0050	14		А		2002	0919		ZA.	2001-	5014			2	0010	619
2001	PA06	328		Α		2001	0910		MX :	2001-	PA63.	28		2	0010	620
2001	CNOO	859		A		2005	0304		IN.	2001-	CN85	9		2	0010	620
2001	0031	00		A		2001	0821		NO .	2001-	3100			2	0010	621
2003	1995	20		A1		2003	1023		US :	2002-	2672	92		2	0021	009
6844	366			BZ		2005	0118									
2003	2164	35		A1		2003	1120		US	2002-	2677	27		2	0021	009
6787	559			В2		2004	0907									
Y APP	LN.	NFO	. :						US	1998~	1133	11P	1	P 1	9901	222
									US	1999-	1470	53P		1	9990	803
									US	1999-	1641	38 P		. 1	9991	108
									WO	1999-	EP99	20		. 1	9991	214
Y APP		.N. :	.N. INFO	N. INFO.:	166 B2 20050118 116405 A1 20031120 559 B2 20040907 .N. INFO.:	.N. INFO.: US US US WO	N. INFO.: US 1998- US 1999- US 1999- WO 1999-	N. INFO.: US 1998-1133 US 1999-1470 US 1999-1641 WO 1999-EP99	.M. INFO.: US 1998-113311P US 1999-147053P US 1999-164138P WO 1999-EP9920 US 1999-469660	.N. INFO.: US 1998-113311P US 1999-147053P US 1999-147053P US 1999-164138P WO 1999-EP9920 US 1999-EP9920 US 1999-EP9920	N. INFO.: US 1998-113311P P 1 US 1999-147053P P 1 US 1999-164138P P 1 W0 1999-EP9920 W 1	N. INFO.: US 1998-113311P P 19981 US 1999-147053P P 19990 US 1999-164138P P 19991 WO 1999-EP992O W 19991 US 1999-469660 A3 19991				

OTI I T 730404613; 279254-86-3P 279254-88-5P 279254-89-6P 279254-90-9P 279254-91-0P 279254-92-1P 279254-97-6P 279254-98-7P 279255-15-1P 279255-02-6P 279255-03-7P 279255-15-1P ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

591766-23-3 CAPLUS
1-Fiperazinepentanamide, a-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl) sulfonyl]amino]-N-hydroxy-4-[[(3-methoxyphenyl) amino]carbonyl]-8-oxo-, (aR)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
279255-16-2P 279255-21-9P 279255-25-3P
279255-56-0P 279255-58-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SFN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-procelianse)
279254-86-3 CAPLUS
1-Piperazinocarboxylic acid, 4-[4R]-4-[(1,3-benzodioxol-5-ylmethyl)](4-methoxy-2,3,6-trimethylphenyl)sulfonyl]aminol-5-(hydroxyamino)-1,5-dioxopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

279254-88-5 CAPLUS l-Piperazinepentanamide, N-hydroxy- α -[[4-methoxyphenyl]sulfonyl][4-methyl-3-nitrophenyl]methyl]amino]- δ -oxo-4-phenyl-, (α R)- (9CI) (CA INDEX NAME)

279254-89-6 CAPLUS 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl]sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, methylester (9C1) (CA INDEX NAME)

Absolute stereochemistry.

RN 279254-90-9 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-{{(3-fluorophenyl}methyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-οxο-, (αR)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.

RN 279254-91-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 279254-98-7 CAPLUS
CN 1-Piperazinepentanamide, a-[[(3-fluorophenyl)methyl][(4-methoxyphenyl)mulfonyl]aminoj-N-hydroxy-8-oxo-4-(2-pyridinyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 279255-01-5 CAPLUS
CN 1-Piperazinepentanamide, α-[{(3-fluorophenyl)methyl}{(4-methoxy-2,3,6-trimethylphenyl)aulfonyl}amino]-N-hydroxy-8-oxo-4-(2-pyridinyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 279254-92-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4R]-4-[[3-fluorophenyl]methyl][(4-methoxyphenyl)sulfonyl]smino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9Cl) (CA INDEX NAME)

Absolute stereochemistry.

RN 279254-97-6 CAPLUS
CN 1-Piperazinepentanamide, a-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethyl)phenyl)sulfonyl}amino]-N-hydroxy-8-oxo-4-phenyl-, (aR)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 279255-02-6 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-a-[[(3-fluorophenyl]methyl][(4-methoxyphenyl)mulfonyl]mino]-N-hydroxy-8-oxo-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 279255-03-7 CAPLUS

CN 1-Piperazinepentanamide, 4-acetyl-a-{(1,3-benzodioxol-5-ylmethyl)[{4-methoxy-2,3,6-trimethyl)phenyl}sulfonyl]amino]-N-hydroxy-5-oxo-,
(aR)- {9Cl} (CA INDEX NAME)

Absolute stereochemistry.

RN 279255-15-1 CAPLUS
CN 1-Piperazinepentanamide, α-{(1,3-benzodioxol-5-ylmethyl)}(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-4-{({4-methylphenyl)amino]carbonyl}-8-oxo-, (αR)- (9Cl) (CA INDEX NAME)

Absolute stereochemistry.

RN 279255-16-2 CAPLUS
1-Piperazinepentanamide, α-[{1,3-benzodioxol-5-ylmethyl}]{{4-methoxy-2,3,6-trimethylphenyl}aulfonyl}amino]-N-hydroxy-4-[{(3-methoxyphenyl}amino]carbonyl]-δ-οxo-, (αR)- {9CI} (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued).

RN 279255-56-0 CAPLUS CN 1-Piperazinepentanamide, α -{(1,3-benzodioxol-5-ylmethyl)} [4-methoxyphenyl] sulfonyl]amino]-4-benzoyl-N-hydroxy-8-oxo-, (α R)- (9Cl) (CA INDEX, NAME)

Absolute stereochemistry.

RN 279255-58-2 CAPLUS

1-Piperazinepentanamide, a-{(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-(2-furanylcarbonyl)-N-hydroxy-5-oxo-, (aR)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

RN 279255-21-9 CAPLUS
CN 1-Piperazinepentanamide, a-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-5-oxo-4-(phenoxyacetyl)-, (aR)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

RN 279255-25-3 'CAPLUS
CN 1-Piperazinepentanamide, a-[(1,3-benzodioxol-5-ylmethyl){(4-methoxy-2,3,6-trimethylphenyl]sulfonyl]amino]-N-hydroxy-4-(methylsulfonyl)-8-oxo-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued

REFERENCE COUNT:

11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2000:96004 CAPLUS DOCUMENT NUMBER: 132:151682

DOCUMENT NUMBER: TITLE:

132:151692
Preparation of sulfonylaminoalkanediamides and related compounds as matrix metalloproteinase inhibitors.
Beckett, Raymond Pauly Martin, Fionan Mitchell;
Miller, Andrew Todd, Richard Simon; Whittaker, Mark
British Biotech Phermaceuticals Ltd., UK
U.S. 32 pp., Cont.-in-part of Ser. No.
Wo97GB-9702891. INVENTOR (S):

PATENT ASSIGNEE(S):

CODEN: USXXAM Patent English 3 DOCUMENT TYPE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. XIND DAID

US 6022873 A 20000208 US 1998-121033 19980723
W0 9817655 A1 19980430 W0 1997-082891 19971020
W: AU, BR, CA, CN, CZ, DE, GB, GE, HU, IL, JP, KR, MX, NO, NZ, PL,
RU, SG, SK, TR, UA, US
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, HC, NL, PT, SE
PT 1030842 T 20030731 PT 1997-912351 19971113
ES 2195122 T3 20031201 ES 1997-912351 19971113
PRIORITY APPLN. INFO: GB 1996-21814 A 19961019
W0 1997-082891 A2 19971020
EP 1997-912351 A 19971113

· Absolute stereochemistry.

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN Absolute stereochemistry.

206553-66-4 CAPLUS 1-Piperidinebutanamide, α -{{{{4-chloro-2,5-dimethylphenyl}oulfonyl]methylamino]methyl}-N-hydroxy- β -{2-methylpropyl}- γ -oxo-, (α R, β R)- (9CI) (CA INDEX NAME)

206553-67-5 CAPLUS 1-Piperidinebutanam.de, α -{{{2,5-dimethoxyphenyl} sulfonyl}methylaminojmethyl}-N-hydroxy- β -{2-methylpropyl}- γ -oxo-, { α R, β R}- {9CI} (CA INDEX NAME)

Absolute stereochemistry.

206553-68-6 CAPLUS l-Piperidinebutanamide, N-hydroxy- β -{2-methylpropyl}- α -{methyl}(8-quinolinylsulfonyl)amino]methyl}- γ -oxo-, (α R, β R) - {9CI} (CA INDEX NAME)

Absolute stereochemistry.

(Continued)

ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued 206553-55-1 CAPLUS 1-Piperidinebutanamide, N-hydroxy- α -{2-{{(4-methylpmino)+proximal (ABP)}- β -{2-methylpropyl}- γ -oxo-, (α S, β R)- {9CI} (CA INDEX NAME)

Absolute stereochemistry.

206553-57-3 CAPLUS
1-Fiperidinebutanamide, N-hydroxy-a-[[[(4-methyylpropyl]sulfonyl]methyylpinyl]sulfonyl]methyllamino]methyl]- β -(2-methylpropyl)-y-oxo-, (aR, β R)- [9CI] (CA INDEX NAME)

Absolute stereochemistry.

206553-63-1 CAPLUS l-Piperidinebutanamide, α -{[{{4-butoxyphenyl}sulfonyl}methylamino}methyl-n-hydroxy- β -{2-methylpropyl}- γ -oxo-, { α R, β R}-{9CI} (CA INDEX NAME)

Absolute stereochemistry.

206553-64-2 CAPLUS 200393-04-2 CARDOS l-Piperidinebutanamide, $\alpha-[\{\{\{2-chloro-5-\{trifluoromethyl]phenyl\}sulfonyl]methylamino]methyl]-N-hydroxy-<math>\beta-\{2-methylpropyl\}-\gamma-oxo-$, $\{\alpha R, \beta R\}-\{9CI\}$ (CA INDEX NAME)

ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

206553-70-0 CAPLUS 1-Piperidinebutnamide, $\alpha-[[\{\{4-chlorophenyl\}sulfonyl]methylamino]methyl]-N-hydroxy-<math>\beta-\{2-methylpropyl\}-\gamma-oxo-, (\alpha R, \beta R\}-\{SCI) (CA INDEX NAME)$

206553-72-2 CAPLUS 1-Piperidinebutanamide, $\alpha-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-B-(2-methylpropyl)-y-oxo-, <math>(\alpha R, \beta R)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 206553-74-4 CAPLUS

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl (2-naphthalenylaulfonyl) aminol methyl]-β-(2-methylpropyl)-γ-οχο-,
(αR, RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry

Absolute stereochemistry.

RN 206553-76-6 CAPLUS

1-Piperidinebutanamide, α-[[[(5-chloro-2-methoxyphenyl)]=uplfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-οxo-, (αR, RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 206553-77-7 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[4-(1,1-dimethylpropyl)phenyl]sulfonyl]methyll-N-hydroxy-β-(2-methylpropyl)-γ-οκο-, (αR, βR) - (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 244296-06-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[ethyl](4-methoxyphenyi)sulfonyl]amino]methyl]-N-bydroxy-β-(2-methylpropyl)-γ-οκο-, (αR, βR)-(9C1) (CA INDEX NAME)

Absolute stereochemistry.

RN 244296-07-9 CAPLUS
CN 1-Piperidinebutanamide, β-{cyclopentylmethyl}-α-{{ethyl{4-nethoxyphenyl}oulfonyl}amino|methyl}-N-hydroxy-y-cxo-, (αR, βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued

Absolute starsochamistry

RN 206553-78-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[([1,1'-biphenyl]-4-ylsulfonyl)methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-οxο-, (αλ,βλ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 206553-81-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-{{methyl{4-methylphenyl}=y-oxo-, (αR, βR} - (9CI) (CA INDEX NAME)} - (2-methylpropyl)-y-oxo-,

Absolute stereochemistry.

RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[{{(4-methoxyphenyl) aulfonyl)methylamino|methyl}-γ-οxο-, (αR, βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued),

RN 244296-10-4 CAPLUS
CN 1-Piperidinobutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-οxe-, (αR, RR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 244296-09-1 CMF C29 H42 N4 O5 S

Absolute stereochemistry

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 244296-16-0 CAPLUS CN 1-Piperidinebutanamide, α -[{[[5-(dimethylemino)-1-

ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) naphthalenyl]sulfonyl]ethylamino[methyl]-N-hydroxy-β-{2-methylpropyl}-γ-οχο-, (αR, βR) - [9CI) (CA INDEX NAME)

Absolute stereochemistry.

CM 1

CRN 244296-16-0 CMF C28 H42 N4 O5 S

Absolute stereochemistry.

2 CRN 76-05-1 CMF C2 H F3 O2

ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

244296-26-2 CAPLUS l-Piperidinebutanamide, β -{cyclopentylmethyl}-N-hydroxy- α -{{{S-isquinolinylsulfonyl}methylamino}methyl}- γ -oxo-, { α R, β R}- {9Cl} (CA INDEX NAME)

Absolute stereochemistry.

244296-27-3 CAPLUS 1-Piperidinebutanamide, β -(cyclopentylmethyl)- α -[[[[6-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-y-oxo-, $(\alpha R, \beta R)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

206553-91-5P 206553-96-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of sulfonylaminoalkanediamides and related compds. as matrix metalloproteinase inhibitors)

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

244296-22-8 CAPLUS 1-Piperidinebutanamide, $\alpha-\{[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-\beta-(cyclopentylmethyl)-N-hydroxy-y-oxo-, <math>(\alpha k, \beta R)-(9C1)$ (CA INDEX NAME)

Absolute stereochemistry.

244296-23-9 CAPLUS 1-Piperidinebutanamide, β -(cyclopentylmethyl)-N-hydroxy- α -[methyl[8-quinolinylsulfonyl]amino]methyl]- γ -oxo-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

244296-25-1 CAPLUS 1-Piperidinebutanamide, β -{cyclopentylmethyl}-N-hydroxy-q-{methyl}{1-naphthalenylmulfonyl}amino|methyl}- γ -oxo-, {qR, β R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) 206553-91-5 CAPLUS 1-Fiperidinebutanoic acid, α -[3-[[(4-methoxyphenyl)sulfonyl]methylam ino]propyl]- β -(2-methylpropyl)- γ -oxo-, 1,1-dimethylethyl ester, (α S, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

206553-96-0 CAPLUS 1-Piperidinebutanoic acid, α -{[[(4-methoxyphenyl)sulfonyl|methylamin o]methyl}- β -(2-methylprqpyl)- γ -oxo-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 18
ACCESSION NUMBER:
DOCUMENT NUMBER:
1171LE:
11999:662331 CAPLUS
12:30315
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors
AUTHOR(S):

AUTHOR(S):

Hartin, Fiona M., Beckett, R. Paul Bellamy, Claire
L.; Courtney, Paul F., Davies, Stephen J.; Drummond, Alan H.; Dodd, Rory; Pratt, Liza M.; Patel, Sanjay R.; Ricketts, Michelle L.; Todd, Richard S.; Tuffnell, Andrew R.; Ward, John W. S.; Whittaker, Mark
British Biotech Pharmaceuticals Limited, Oxford, OX4
SLY, UK
SOURCE:
Bioorganic & Madicinal Chemistry Letters (1999), 9(19), 2887-2892
CODEN: EMCLEB; ISSN: 0960-894X
Elsevier Science Ltd.

PUBLISHER: Elsevier Science Ltd.

MENT TYPE: Journal
UMGE: English
206553-57-3P 206553-72-2P 244296-01-3P
244296-09-1P 244296-22-8P
244296-09-1P 244296-22-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and biol. evaluation of non-peptidic matrix metalloproteinase inhibitors in relation to oral bioavailability)
206553-57-3 CAPLUS
1-Fiperidinebutanamide, N-hydroxy-α-[[(4-methylpropyl)-y-oxo-, (αR,PR)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

206553-72-2 CAPLUS l-PiperidineDutamide, α -[[[5-(dimethylamino)-l-naphthalen]]sulfonyl]methylamino]methyl]-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (α R, β R)- [9CI) (CA INDEX NAME)

Absolute stereochemistry.

AMSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) 244296-22-8 CAPLUS
1-Piperidinebutanamide, a-[[[{4-chlorophenyl}]sulfonyl]methylamino]methyl]-B-(cyclopentylmethyl)-N-hydroxy-y-oxo-, (aR,RR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

244296-01-3 CAPLUS 1-Piperidinebutanamide, β -(cyclopentylmethyl)-N-hydroxy- α -{[[(4-methoxyphenyl)sulfonyl]methylamino]methyl}- γ -oxo-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

244296-09-1 CAPLUS
1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-cxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN SSION NUMBER: 1999:626184 CAPLUS HENT NUMBER: 131:242793

ACCESSION NUMBER: DOCUMENT NUMBER: TITLE:

Preparation of hydroxamic acids and carboxylic a as metalloproteinase inhibitors Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew: Todd, Richard Simon British Biotech Pharmaceuticals Limited, UK PCT Int. Appl. 52 pp. CODEN: PIXXD2 Patent Preparation of hydroxamic acids and carboxylic acids

INVENTOR(S):

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 9948881 A1 19990930 WO 1998-GB914 19980325

W: AU, BR, CA, CX, CZ, HI, 1L, JP, KR, HX, NO, NZ, PL, RU, SG, SK, TR
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, FT, SE
AU 9868435 A 19991018 AU 1998-68435 19980325

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NI, SE, FT, IE, FI
JP 2003522723 T 20030729 JP 2000-537864 19980325

RRIORITY APPLIN. INFO:. 20030729 JP 2000-537864 19980325

RI 244296-01-3P 244296-06-8P 244296-10-9P
244296-01-3P 244296-20-8P 244296-23-9P
244296-17-1P 244296-22-8P 244296-23-9P
244296-25-1P 244296-22-8P 244296-28-4P
RLI BAC (Biological activity or effector, except adverse); BSU (Biological study), unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USS (Uses)
(preparation of hydroxamic acids and carboxylic acids as
metalloproteinase inhibitors)
RN 244296-01-3 CAPLUS

N1 - Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[{{4-methoxyphenyl} sulfonyl|methylamino|methyl]-γ-οxo-,
(GR, RR)- (SCI) (CX: INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.

244296-06-8 CAPLUS 1-Piperidinebutanamide, α -{[ethyl{(4-methoxyphenyl) sulfonyl}amino]methyl}-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, $(\alpha R, \beta R)$ -(SCI) (CA INDEX NAME)

Absolute stereochemistry.

244296-07-9 CAPLUS l-Piperidinebutanamide, β -(cyclopentylmethyl)- α -{{ethyl}{4-methoxyphenyl}sulfonyl]amino]methyl}-N-hydroxy- γ -oxo-, (ak, β R)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

244296-09-1 CAPLUS 1-Piperidinebutanamide, β -(cyclopentylmethyl)- α -{{{{5-(dimethylamino)-1-naphthalenyl}sulfonyl}methylamino}methyl}-N-hydroxy-y-oxo-, $(\alpha R, \beta R)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

244296-10-4 CAPLUS 1-Piperidinebutanamide, β -(cyclopentylmethyl)- α -[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl-N-hydroxy- γ -cxc-, (aR,RR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN L4 (Continued)

244296-17-1 CAPLUS 1-Piperidinebutanamide, α -[[[[S-{dimethylamino}-1-naphthalenyl]sulfonyl}ethylamino]methyl]-N-hydroxy- β -{2-methylpropyl}- γ -oxo-, (AR, RR]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 244296-16-0 CMF C28 H42 N4 O5 5

Absolute stereochemistry.

2 CM

CRN 76-05-1 CMF C2 H F3 O2

244296-22-8 CAPLUS l-Piperidinebutanamide, $\alpha-[[\{\{4-chlorophenyl\}sulfonyl\}methylamino]methyl]-\beta-[cyclopentylmethyl]-N-hydroxy-<math>\gamma$ -oxo-, $\{\alpha R, \beta R\}-\{9CI\}$ (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

2 CM

CRN 76-05-1 CMF C2 H F3 O2

244296-16-0 CAPLUS 1-Piperidinebutanamide, α -[[[[5-{dimethylamino}]-1-naphthalenyl]sulfonyl]ethylamino]methyl}-N-hydroxy- β -{2-methylpropyl}- γ -oxo-, $(\alpha R, \beta R)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

244296-23-9 CAPLUS 1-Piperidinebutanamide, β -{cyclopentylmethyl}-N-hydroxy- α -{methyl}{8-quinolinylsulfonyl}amino]methyl}- γ -oxo-, { α R, β R}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

244296-25-1 CAPLUS 1-Piperidinebutanamide, β -{cyclopentylmethyl}-N-hydroxy- α -{methyl{-naphthalenyloulfonyl}amino|methyl}- γ -oxo-, { α R, β R}- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

244296-26-2 CAPLUS
1-Fiperidinebutanamide, B-(cyclopentylmethyl)-N-hydroxy-a-[[{5-isoquinolinylsulfonyl)methylamino]methyl]-y-oxo-,
(aR, BR)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.

244296-28-4 CAPLUS 1-Piperidinebutanamide, β -(cyclopentylmethyl)- α -[[[[6-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy- γ -oxo-, (α R, β R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CRN 244296-27-3 CMF C29 H42 N4 O5 S

Absolute stereochemistry.

СМ 2

CRN 76-05-1 CMF C2 H F3 02

IT 206553-96-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxamic acids and carboxylic acids as metalloproteinase

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:460409 CAPLUS

DOCUMENT NUMBER: 131:87805

ITITLE: Preparation of amprenavir prodrugs as HIV protease inhibitors

INVENTOR(S): Tung, Royer D., Hale, Michael R., Baker, Christopher T., Furfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Wieczyslaw; Spaltenstein, Andrew Vertex Pharmaceuticals Incorporated, USA PCT Int. Appl., 110 pp.

DOCUMENT TYPE: Patent

DOCUMENT TYPE: Patent English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.					KIN	D	DATE			APF	LICAT	ION	NO.			ATE	
											1998						
	W:	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BF	, BY,	CA,	CH,	CN,	CU,	CZ,	DE,
		DK,	EE,	ES,	FI,	GB,	GE,	GH,	GM,	GW	, HU,	ID,	IL,	IS,	JP,	KE,	KG,
		KP,	KR,	KZ,	LC,	LK.	LR,	LS,	LT,	LU	, LV,	MD,	MG,	MK,	MN,	MW,	MX,
		NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG	, SI,	SK,	SL,	TJ,	TM,	TR,	TT,
		UA,	UG,	US,	UZ,	VN,	YU,	2W									
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SZ,	UG,	24	, AT,	BE,	CH,	DE,	DK,	EŞ,	FI,
											, SE,	BF,	BJ,	CF,	CG,	CI,	CM,
		GA,	GN,	ML,	MR,	NE,	SN,	TD,	TG								
US	6436	989			B1		2002	0820		US	1997-	9980	50		1	9971	224
ΑU	9865	466			A		1999	0719		ΑU	1998-	-6546	6		1	9980	309
ΑU	7550	87			B2		2002	1205									
TR	2000	0261	5		T2		2001	0122		TR	2000-	-2000	0261	5	1	9980	309
BR	9814	480			Α		2001	0925		BR	1998-	1448	0		1	9980	309
EE	2000	0038	5		A		2001	1217		EE	2000-	-385			1	9980	309
EΕ	4466				В1		2005	0415									
Hυ	2001	0183	1		A2		2002	0429		HU	2001-	-1831			1	9980	309
ΗU	2001	0183	1		A3		2002	0828									
ΑP	1172				Α		2003	0630		ΑP	1997- 1998- 2000- 1998- 2000- 2001-	1850			1	9980	309
	W:	GH,	GM,	ΚE,	LS,	MW,	SD,	SZ,	ŲG,	ZW	,						
ΝZ	5057	76			A		2003	0630		NZ	1998 - 1998 - 1998 -	-5057	76		1	9980	309
CA	2231	700			С		1999	0624		CA	1998	2231	700		1	9980	310
CA	2231	700			A1		1999	0624					_				
JP	1120	9337			Α.		1999	0803		JР	1998-	-5870	5		1	9980	310
JP	3736	964			B2		2006	0118									
EP	9333	72_			A1		1999	0804		EP	1998-	1042	92		1	9980	310
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GF	, IT,	LI,	ĻŪ,	ΝL,	SE,	MC,	PT,
		IE,	51,	LT,	ĽV,	FI,	RO										
TW	4804	74			ь		2002	0211		TW	1998.	.8/12	1460			3981	222
ZA	9811	4101	220		^		2000	0623		ZA	1998-	1183				9981	443
IN	1998	0002	210		^		2005	0021		IN	1998	-CA22	10			3381	223
NO	2000	0033	315		•		2000	0821		NU	2000	-3304	١.		-	0000	623
MA.	2000	177	315		Α,		2001	0519		mA.	2000	FROJ	15		-	00000	623
05	1046	231			ь.		2003	0300		03	2000-	1044	21		-	0000	723
DC	6406	21			۸,		2001	0220		ÞG	2000-	- 1040	31		-	0000	124
110	2003	9 2070	71		D 1		2000	1106		110	2002.	. 2701	71		-	0030	210
116	6030	20'0 474	, .		B 2		2003	0104		05	1998- 1998- 1998- 2000- 2000- 2000- 2003- 2004- 2005- 1997- 1998-	-5,01	, ,		-	,0030	419
119	2005	1495	48		D2		2005	0104		115	2004	.0582	23		,	0041	004
.ID	2005	3504	78		2,		2005	1222		.10	2004	2050	07			0041	717
17	ADD.	IN	INFO		^		2003			HC.	1007	.0000	50		A 2 1	0071	224
				• •						Wn.	1996	11945	95		u 1	0000	300
										10	1000	5070	50		~ 1	9980	310
										UF	1330.	30,0	•		~ 1	330U	2.0

ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) inhibitors) 205553-96-0 CAPLUS 1-Piperidinebutanoic acid, a-{[[(4-methoxyphenyl)sulfonyl]methylamin o]methyl]-P-(2-methylpropyl)-y-oxo-, (aR, RR)- (9CI) (CA INDEX NAME)

IT 206553-57-3P
RL: SPN (Synthetic preparation): PREP (Preparation)
(preparation of hydroxamic acids and carboxylic acids as
metalloproteinase

lioproteinase inhibitors) 206553-57-3 CAPLUS 1-Piperidinebutanamide, N-hydroxy- α -[{[{4-methylporpyl}- γ -oxo-, { α R, β R}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

3

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN US 2000-602494 US 2003-370171 (Continued) A3 20000623 A3 20030219

OTHER SOURCE(s): MARPAT 131:87805

IT 229495-38-9P 229495-43-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological activity or effector, except adverse); BSU (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological atudy); PREP (Preparation); USES (Uses)
(preparation of amprensvir prodruga as HIV protease inhibitors)
RN 229495-38-9 CAPLUS

N-Piperazinecarboxylic acid, 4-methyl-, (1R, 25)-1-{{{(4aminophenyl)sulfonyl](2-methylpropyl)amino|methyl|-3-phenyl-2-[[{{(35)tetrahydro-3-furanyl]oxylcarbonyl]amino|propyl ester, trifluoroacetate
(10:19) (9CI) (CA INDEX NAME)

CM 1

CRN 229495-37-8 CMF C31 H45 N5 O7 S

Absolute stereochemistry.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

C- CO2H

229495-43-6 CAPLUS
1-Piperazinearboxylic acid, (1R,25)-1-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino|methyl]-3-phenyl-2-[[[([35)-tetrahydro-3-furanyl]oxylcarbonyl]amino|propyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) Absolute stereochemistry

CM 2 CRN CMF 76-05-1 C2 H F3 O2

REFERENCE COUNT:

(Continued)

ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN NAME)

Absolute stereochemistry.

229495-42-5 CAPLUS
1-Piperazinecarboxylic scid, (1R,2S)-1-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]methyl)-3-phenyl-2-[[[([3S)-tetrahydro-3-furanyl]oxy|carbonyl]amino]propyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1999:460393 CAPLUS 131:97804 TITLE: Preparation of 10 CT Preparation of 1,3-diacylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors. Hale, Michael R.: Tung, Roger D.: Baker, Christopher T.: Spaltenstein, Andrew: Furfine, Eric Steven: Kaldor, latvan: Karmierski, Wieslaw Hieczyslaw Vertex: Pharmaceuticals Incorporated, USA PCT Int. Appl., 86 pp. CODEN: PIXXD2
Patent
English INVENTOR (5) : PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: LANGUAGE: English 1 FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO KIND DATE APPLICATION NO. DATE WO 9933793 WO 9933793 19990708 19981223 A2 A3 WO 1998-US27424 AL, DK, KE, W: 19981223 20000626 20000713 20000724 20011130 20020821 P 19971224 W 19981223 A1 20000623 B1 20011130 CN 1998-813313
MX 2000-PAG316
NO 2000-3332
IN 2000-RN131
HR 2000-499
US 2001-998617
US 2002-226430
US 1997-688899
VO 1998-US27424
US 2000-602984
US 2001-998617 OTHER SOURCE(s):

MARPAT 131:87804

17 229495-37-8P 229495-42-5P
RL: BAC (Biological activity or effector, except adverse): BSU (Biological study, unclassified): SPN (Synthetic preparation): THU (Therapeutic use):
BIOL (Biological study): PREP (Preparation): USES (Uses)
(preparation of 1,3-discylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors)
RN 229495-37-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-methyl-, (1R,2S)-1-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)aminolmethyll-2-phenyl-2-[[[(3S)-tetrahydro-3-furanyl]oxylcarbonyl]aminolpropyl ester (9CI) (CA INDEX

L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:460392 CAPLUS
131:87803
ITITLE: produced of 1,3-diacylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors.
INVENTOR(S): Hale, Michael R., Tung, Roger inhibitors.
Hale, Michael R., Tung, Roger D. Baker, Christopher T., Spaltenstein, Andrew, Purfine, Eric Steven, Kaldor, Istvan, Kazmierski, Wieslaw Mieczyslaw Vertex Pharmaceuticals Incorporated, USA PCT Int. Appl., 109 pp.
CODEN: IXXD2
DOCUMENT TYPE: Patent INVENTOR PATENT INFORMATION:
English
FAMILUT ACC. NUM. COUNT:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 9933792 A2 19990708 WO 1998-US27403 19981223
WO 9933792 A3 19990916
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KF, KR, KZ, LC, LK, KR, LS, LT, LU, LV, MD, MG, MK, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TJ, TM

RU: GH, GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, HC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GM, GW, ML, MR, NE, SN, TD, TG

AU 9920102 A 19990719 AU 1999-20102 19981223

PRIORITY APPLM. INFO: US 131:87803

OTHER SOURCE(s): MARPAT 131:87803 W 1998-US27403 W 19981223

OTHER SOURCE(s): MARPAT 131:87803

IT 229495-37-8P 229495-42-5P
RL: BAC (Biological activity or effector, except adverse): BSU (Biological study, unclassified): SPN (Synthetic preparation): THU (Therapeutic use):
BIOL (Biological study): PREP (Preparation): USES (Uses)
(preparation of 1,3-diacylamino-2-acyloxypropanes as prodruge of aspartyl protease inhibitore)

RN 229495-37-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-methyl-, (1R,2S)-1-[[[4-aminophenyl]sulfonyl](2-methylpropyl)amino|methyll-3-phenyl-2-[[[(33)-tetrahydro-3-furanyl]oxylcarbonyl]amino|propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry

ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

229495-42-5 CAPLUS
1-Piperazinecarboxylic acid, (1R,2S)-1-[[[(4-aminophenyl)sulfonyl](2-methylproyl)amino|methyl]-3-phenyl-2-[[[[(3S)-tetrahydro-3-furanyl]oxylcarbonyl]amino]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

206553-55-1 CAPLUS l-Piperidinebutanamide, N-hydroxy- α -[2-[[4-methoxphenyl]sulfonyl]methylamino|ethyl]- β -(2-methylpropyl)- γ -oxo-, (α S, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

206553-57-3 CAPLUS l-Piperidinebutanamide, N-hydroxy-a-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]- β -(2-methylpropyl)- γ -oxo-, (aR, β R)- (9C1) (CA INDEX NAME)

Absolute stereochemistry

206553-63-1 CAPLUS l-Piperidinebutanamide, α -[[[(4-butoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-P-(2-methylpropyl)- γ -oxo-, (α R, β R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1998:268494 CAPLUS DOCUMENT NUMBER: 128:308398

DOCUMENT NUMBER: TITLE:

INVENTOR(5):

128:308398
Preparation of hydroxamides as metalloproteinase inhibitors
Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark British Biotach Pharmaceuticals Ltd., UK: Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark PCT Int. Appl., 70 pp.
CODEN: PIXXD2
Patent PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE: LANGUAGE:

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PA1	ENT I																		
	9817																		
	W:	ΑU,	BR,	CA,	CN,	CZ,	DE,	GB,	GE,	нι	Ι, Ι	L,	JP,	ĸĸ,	ΜX,	NO,	NZ,	PL,	
		RU,	SG,	SK,	TR,	UA,	US												
	RW:	AT.	BE.	CH.	DE.	DX.	ES.	F1.	FR.	GE	s. G	R.	IE.	IT.	LU.	MC.	NL.	PT.	SE
CA	22692	283			Al		1998	0430		CA	199	7-2	2269	283		1	9971	020	
Att	9747	142			Ä.		1998	0515		AII	199	7-	714	2		i	9971	020	
ATT	22692 97473 71360	17			B2		1000	1200			•••			-		•			
CD	23240	101			2.		1000	1014		C D	100					٠,	0071	020	
0.0	23240	731			•		1990	1014		uв	133	,,,,	1001	•			9911	020	
GB	23240	191			ь		2000	1115											
	93429									EΡ	199	17-9	3094	61		1	9971	020	
EP	93429	92			B1.		2006	0315											
								FR,											FΙ
NZ	3347	11			A		2000	1027		NZ	199	17-:	3347	11		1	9971	020	
JP	3347: 2001: 3204: 1030:	5023	48		T		2001	0220		JР	199	8-5	191	12		1	9971	020	
AT	32042	22			т		2006	0415		AT	199	7-9	2094	61		1	9971	020	
PT	10306	142			÷		2003	0731		DT	100	7-6	1123	61		i	0071	113	
	2195	22					2002	1201			100	7 .	1122	::		;	0071	113	
	9710																		
	60221				A		2000	0208		US	199	18 -	210	33		1	3380	723	
RIORITY	APP	N.	INFO	. :						GB	199	6-2	2181	4		A 1	9961	019	
										W O	199	17-0	3B28	91		w 1	9971	020	
										EP	199	17-9	123	51		A 1	9971	113	

OTHER SOURCE(S): MARPAT 128:308398 BP 1997-912351 A 19971113

OTHER SOURCE(S): MARPAT 128:308398

IT 206553-64-0P 206553-55-1P 206553-57-3P
206553-63-1P 206553-66-4P 206553-76-0P
206553-67-5P 206553-68-4P 206553-76-0P
206553-72-2P 206553-78-4P 206553-78-8P
206553-76-6P 206553-77-44-P 206553-78-8P
206553-76-6P 206553-77-8-P
206553-81-3P
RL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamides as metalloproteinase inhibitors)
RN 206553-54-0 CAPLUS

N 1-Piperidinebutanamide, N-hydroxy-a-[3-[[4methoxyphenyl]]sulfonyl]methylamino|propyl]-β-(2-methylpropyl)-γNOC-, (αS, βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

206553-64-2 CAPLUS 1-Piperidinebutanamide, $\alpha-[[[[2-chloro-5-\{trifluoromathyl]phenyl]sulfonyl]methylamino|methyl]-N-hydroxy-<math>\beta-(2-methylpropyl)-\gamma-oxo-$, $(\alpha R, \beta R)$ - (9CI) (CA INDEX NAME)

206553-66-4 CAPLUS 1-Piperidi nebutanamide, α -[[[{4-chloro-2,5-dimethylphenyl}]sulfonyl]methylamino]methyl}-N-hydroxy- β -(2-methylpropyl)- γ -oxo-, (α R, β R) - (9CI) (CA INDEX NAME)

206553-67-5 CAPLUS
1-Piperidinebutanamide, α-{[[(2,5-dimethoxyphenyl)sulfonyl]methylaminojmethyl]-N-hydroxy-β-(2-methylpropyl)-γ-οxο-, («R, βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

(Continued)

206553-68-6 CAPLUS
1-Piperidinebutanamide, N-hydroxy-β-(2-methylpropyl)-α-[methyl(8-quinolinylsulfonyl)amino]methyl]-γ-οxο-,
[απ, βπ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

206553-70-0 CAPLUS l-Piperidinebutanamide, α -[[{{4-chlorophenyl}sulfonyl]methylamino]methyl-n-hydroxy- β -{2-methylpropyl}- γ -oxo-, { α R, β R}-{9Cl} (CA INDEX NAME)

Absolute stereochemistry.

RN . 206553-72-2 CAPLUS

1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2methylpropyl)-γ-οκο-, (αR, βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

206553-77-7 CAPLUS

ZUBS33-/-/ APUSS de --[[[[4-(1,1-dimethylpropyl)phenyl]sulfonyl] methylamino|methyl]-ν-οχο-, (αR, R)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.

206553-78-8 CAPLUS 1-Piperidinebutanamide, α -[{{[1,1'-biphenyl}-4-ylsulfonyl]-ethylamino|methyl]-N-hydroxy- β -{2-methylpropyl}-y-oxo-, $(\alpha R, \beta R)$ - {9CI} (CA INDEX NAME)

Absolute stereochemistry.

206553-81-3 CAPLUS l-Piperidinebutanamide, N-hydroxy- α -{{methyl[{4-methylphenyl}=uffonyl}amino]methyl}- β -{2-methylpropyl}- γ -oxo-, {aR, RR}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

206553-74-4 CAPLUS l-Piperidinebutanamide, N-hydroxy- α -{{methyl{2-naphthalenylbulfonyl}amino|methyl}- β -{2-methylpropyl}- γ -oxo-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

206553-75-5 CAPLUS l-Piperidinebutanamide, $\alpha = [[[(3,4-\text{dichlorophenyl})\,\text{sulfonyl}]\,\text{methylamin o]}\,\text{methyl} -N-\text{hydroxy-}\,\beta - (2-\text{methylpropyl})-\gamma-\text{oxo-}, (\alpha R, \beta R)- (9CI) (CA INDEX NAME)}$

Absolute stereochemistry.

206553-76-6 CAPLUS l-Fiperidi nebutanamide, $\alpha-[[[\{5-chloro-2-methoxyphenyl] sulfonyl]nethylamino]nethyl]-N-hydroxy-<math>\beta-\{2-methylpropyl\}-\gamma-oxo-, \{\alpha R, \beta R\}-\{9Cl\}$ (CA INDEX NAME)

ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

206553-91-5P 206553-96-0P RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT (Reactant or reagent) (preparation of hydroxamides as metalloproteinase inhibitors) 206553-91-5 CAPLUS (Preparation of acid, a-[3-[[(4-methoxyphenyl]sulfonyl]methylam ino]propyl]-P-(2-methylpropyl)--y-oxo-, 1.1-dimethylethyl ester, (aS, BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

206553-96-0 CAPLUS 1-Piperidinebutancic acid, α -[[(4-methoxyphenyl)sulfonyl]methylamin o]methyl]- β -(2-methylpropyl)- γ -cxo-, (α R, β R)- {9CI} (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:410405 CAPLUS
DOCUMENT NUMBER: 125:86638
ITITLE: INVENTOR(S): Imidazopyridine derivatives as dual histamine (H1) and platelet activating factor (PAF) antagonists. Miller, Andrew Bowles, Stephen Arthur, Ayscough, Andrew Paul; Whittaker, Mark
British Biotech Pharmaceuticals Limited, UK
PATENT TYPE: CODEN: PIXXD2
DOCUMENT TYPE: CODEN: PIXXD2
DATENT INFORMATION: English
TAMELLY ACC. NUM. COUNT: 1
PATENT INFORMATION:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 960520.

W: AU, CA, CN, CZ, DE, FI, GB, HU, JP, KR, NO, NZ, PL, RU, US

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9531863 A 19960307 AU 1995-31863 19950809

EP 775139 A1 19970528 EP 1995-921872 19950809

ER: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE

US 5753671 A 19980519 US 1997-776783 19970210

PRIORITY APPLN. INFO.: GB 1994-16143 A 19940810

OTHER SOURCE(S): HARPAT 125:86638 PATENT NO.

OTHER SOURCE(S): MARPAT 125:86638

IT 178416-74-59 178416-85-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological activity), BIOL (Biological activity), PREP (Preparation); TRU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs, as dual antihistamines and PAF antagonists)
RN 178416-74-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cycloheptall,2-b)pyridin-1-ylimethylphenylsulfonyllaminolpentyl ester, (S)- (9Cl) (CA INDEX NAME)

Absolute stereochemistry.

178416-85-8 CAPLUS

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:
1994:107072 CAPLUS
120:107072 CA

Patent

English

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

						•															
	PAT	ENT	NO.					DATE			APP	LICA	TIO	N 1	ю.			DAT	E		
	•						+	~													
	WO	9316											-GB	273	3			199	302	10	
		w:	AU,	CA,	FI,	JP,	KR,	NO,	NŻ,	PT,	ŲS	;									
				BE,	CH,			ES,													
	ΑU	9334	599			A		1993	0903	1	ΑU	1993	-34	599				199	302	10	
		6622						1995													
	EP	6350	19			A1		1995	0125	1	ĒΡ	1993	-90	326	51			199	302	10	
	EP	6350	18			B1		1999	1222												
		R:	AT:	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GF	, IE	. 1	Γ.	LI.	LU.	NI	P	Τ.	SE	
	JP	0750	3954			T		1995	0427	٠.	JΡ	1993	-51	385	9			199	302	10	
	AT	1879	66			T		2000	0115		٩T	1993	-90	326	1			199	302	10	
	ES	2142	861			Т3		2000	0501	1	ES	1993	-90	326	51			199	302	10	
	US	5516	783			A		1996	0514		JS	1994	-28	157	0			199	410	27	
PRIO	RIT	/ APP	LN.	INFO	. :					(3B	1992	-27	91			٨	199	202	11	
										- 1	Ø0	1993	-GB	273	ı		A	199	302	10	

OTHER SOURCE(S): MARPAT 120:107072

IT 151916-56-2P

RL: BAC (Bological activity or effector, except adverse); BSU (Biological activity or effector, except adverse); BSU (Biological activity); PREP (Preparation); THU (Therapeutic use); BIOL (Biological actual); PREP (Preparation); USES (Uses) (preparation of, as platelet-activating factor antagonist)

RN 151916-56-2 CAPLUS

CN 14-Piperazineducarboxylic acid, ethyl 4-methyl-2-[methyl[4-{(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl]methyl]phenyl]sulfonyl]amino]pentyl ester, (S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Piperidine, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-'
11-ylidene)-1-[[4-methyl-2-[methyl[4-[(2-methyl-1H-imidazo[4,5-c]pyridin1-yl]methyl]phenyl]sulfonyl]amino]pentyl]oxylacetyl}-, (S)- (9CI) (CA
INDEX NAME)

L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:633573 CAPLUS
111:233573
TITLE: Superior of Na-(β-naphthylsulfonylsplycyl)argininamides as potential selective synthetic thrombin inhibitors
AUTHOR(S): Etemad-Moghadam, Guitar Delebassee, Denis Maffrand, Jean Pierre Frehel, Daniel
CORPORATE SOURCE: Lab. Chim. Coord., Univ. Paul-Sabatier, Toulouse, 31400, Fr.

Jah. Chim. Coord., Univ. Paul-Sabatier, Toulouse, 31400, Fr. European Journal of Medicinal Chemistry (1988), 23(6), 577-85

SOURCE:

CODEN: EJMCA5; ISSN: 0223-5234

DOCUMENT TYPE:

Journal English CASREACT 111:233573

Absolute stereochemistry

123760-42-9P 123781-80-6P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and thrombin inhibitory activity of) 123760-42-9 CAPLUS Acetamide, N-[4-[(aminoiminomethyl)amino]-1-(1-piperidinylcarbonyl)butyl]-2-[methyl(2-naphthalenylsulfonyl)amino]-, (S)- (9CI) (CA INDEX NAME)

123781-80-6 CAPLUS

L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Acetamide, N-[4-[(aminoiminomethyl]amino]-1-(1-piperidinylcarbonyl]butyl]2-[methyl(2-naphthalenylsulfonyl)amino]-, monohydrochloride, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry

• KC

=> log y COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 95.80 269.01

STN INTERNATIONAL LOGOFF AT 10:09:44 ON 10 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * Welcome to STN International

NEWS 1 Web Page for STN Seminar Schedule - N. America

NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format

NEWS 3 MAR 16 CASREACT coverage extended NEWS 4 MAR 20 MARPAT now updated daily

NEWS 5 MAR 22 LWPI reloaded

NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements

NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN

NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field

NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records

NEWS 10 APR 30 CA/Caplus enhanced with 1870-1889 U.S. patent records

NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN

NEWS 12 MAY 01 New CAS web site launched

NEWS 13 MAY 08 CA/Caplus Indian patent publication number format defined

NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields

NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data

NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload

NEWS 17 MAY 21 CA/Caplus enhanced with additional kind codes for German patents

NEWS 18 MAY 22 CA/Caplus enhanced with IPC reclassification in Japanese patents

NEWS 19 JUN 27 CA/CAplus enhanced with pre-1967 CAS Registry Numbers

NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available

NEWS 22 JUL 02 LEMBASE coverage updated

NEWS 23 JUL 02 LMEDLINE coverage updated

NEWS 24 JUL 02 SCISEARCH enhanced with complete author names

NEWS 25 JUL 02 CHEMCATS accession numbers revised

NEWS 26 JUL 02 CA/CAplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:52:02 ON 10 JUL 2007

=> file registry COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.21 0.21

COST IN U.S. DOLLARS
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 10:52:08 ON 10 JUL 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4 DICTIONARY FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting ${\tt SmartSELECT}$ searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading C:\Program Files\Stnexp\Queries\10549546c.str

```
chain nodes : .
7 8 10 11 12 19 20 21 22 29 30 31
ring nodes :
1 2 3 4 5 6 9 14 15 16 17 18 23 24 25 26 27 28
chain bonds :
6-7 7-12 7-11 7-30 8-10 8-9 8-19 16-23 19-20 20-21 21-22 22-30 26-29
30-31
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-14 9-18 14-15 15-16 16-17 17-18 23-24 23-28
24-25 25-26 26-27 27-28
exact/norm bonds : 6-7 7-12 7-11 7-30 8-10 8-9 9-14 9-18 14-15 15-16 16-17 16-23 17-18
19-20 20-21 22-30 23-24 23-28 24-25 25-26 26-27 26-29 27-28 30-31
exact bonds :
8-19 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
```


G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS 11:CLASS 12:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:CLASS 30:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=> d 11 L1 HAS NO ANSWERS L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:52:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -11 TO ITERATE

100.0% PROCESSED

11 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 22 TO 418

PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> d scan

5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN Piperazine, 1-[[2-[[(2,4-dichloro-6-methoxyphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-[1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9C1) C22 H34 C12 N4 O5 S . 2 C4 H4 O4

CM 2

Double bond geometry as shown.

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
Piperazine, 1-(1-methyl-4-piperidinyl)-4-[[2-[methyl[{2,4,6-trichlorophenyl]sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI)
C21 H31 Cl3 N4 O4 S . 2 C4 H4 O4

$$\begin{picture}(10,0) \put(0,0){\line(0,0){0.5ex}} \put(0,0){\line(0,0){0.5ex$$

CM 2

Double bond geometry as shown.

5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
Piperazine, 1-{{2-(e-thyl{{a-methoxy-2,6-dimethylphenyl}sulfonyl}amino]etho
xylacetyl]-4-{8-methyl-8-azabicyclo{3.2.l}oct-3-yl)-, (2E)-2-butenedioate
(1:2) (9C1)
C27 H44 N4 O5 S . 2 C4 H4 O4

CM 1

CM 2

Double bond geometry as shown.

S ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN Piperazine, 1-[[2-[[(2,4-dichloro-6-methoxyphenyl]sulfonyl]methylamino]eth oxylacetyl]-4-[1-methyl-4-piperidinyl]- (9C1) C22 H34 C12 N4 O5 S COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Piperazine, 1-[(2-[((4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxylacetyl]-4-[9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, (2E)-2-butenedioate
(1:1) (9Cl)

MF C27 H44 N4 O5 S . C4 H4 O4

CM 2

Double bond geometry as shown.

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 1.80 2.01

FILE 'CAPLUS' ENTERED AT 10:54:37 ON 10 JUL 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jul 2007 VOL 147 ISS 3 FILE LAST UPDATED: 9 Jul 2007 (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> file registry
COST IN U.S. DOLLARS

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.47 2.48

FILE 'REGISTRY' ENTERED AT 10:54:43 ON 10 JUL 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4 DICTIONARY FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting ${\tt SmartSELECT}$ searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s 12 full FULL SEARCH INITIATED 10:54:50 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 135 TO ITERATE

100.0% PROCESSED

135 ITERATIONS

45 ANSWERS

SEARCH TIME: 00.00.01

L3

45 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

.

SESSION

FULL ESTIMATED COST

ENTRY 172.10

174.58

FILE 'CAPLUS' ENTERED AT 10:54:55 ON 10 JUL 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jul 2007 VOL 147 ISS 3 FILE LAST UPDATED: 9 Jul 2007 (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13

L4 2 L3

=> d 14 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:857596 CAPLUS
DOCUMENT NUMBER: 141:350198
TITLE: Heterocyclic (piperazine- and 141:350198

Heterocyclic (piperazine- and piperidine-containing) benzenesulfonamide derivatives, method for their production, therapeutic compositions, and use thereof for treatment of pain and inflammation Barth, Martine, Bondoux, Michel; Doday, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean-Michel
Laboratoires Fournier S.A., Fr.
PCT Int. Appl., 127 pp.
CODEN: PIXXO2
Patent
French

INVENTOR(S):

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE:

French LANGUAGE:

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

TATEM!	INFOR	rini i	O11.														
											LICAT					ATE	
										WO :	2004-	FR72	3		2	0040	324
wo	2004																
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB.	, BG,	BR,	BW,	BY,	BZ,	CA,	CH,
											, EC,						
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	15	, JP,	KE,	KG,	KP,	KR,	KZ,	LC,
		LK,	LR,	LS,	LT,	LU.	LV.	MA,	MD,	MG	, MK,	MN,	MW.	MX.	MZ.	NA.	NI.
		NO.	NZ.	OM.	PG.	PH.	PL.	PT.	RO.	RU	, sc,	SD.	SE.	SG.	SK.	SL.	SY.
											, UZ,						
	RW:										. sz.						
											. BG.						
											, MC.						
											, GN,						
			TG		,	,	,	,	٠,		,,		,	,	,	,	,
FR	2852 2852	958			A1		2004	1001		FR :	2003-	3602			2	0030	325
FR	2852	958			BI		2005										
FR	2853	648			A 1		2004	1015		FR :	2003-	4530			2	0030	411
FR	2853	648			В1		2006	0818							_		
AU	2004	2261	97		A1		2004	1014		AU :	2004 -	2261	97		2	0040	324
CA	2519	110			A1		2004	1014		CA	2004-	2519	110		2	0040	324
EP	1606	288			A1		2005	1221		EP :	2004-	7423	33		2	0040	324
											, IT,						
											TR.						
BR	2004	0086	89	,	Ä		2006	0328	,	BR :	2004-	8689	,	,	,	0040	324
JP	2006	5213	33		т		2006	0921		JP :	2004 - 2006 -	5057	49		5	0040	324
lis	2006	1783	60		A1		2006	กลาก		119 :	2005-	5495	46		,	ስስፍስ	914
NO	2005	0043	61		Α		2005	1101		NO :	2005-	4361	••		5	0050	920
PRIORITY	V APP	I.N .	INFO							FR :	2003-	3602			Δ ²	0030	325
			• • • •							FR	2003-	4530			A 2	0030	411
										vo :	2005 - 2003 - 2003 - 2004 -	FR72	3		A 2	0040	324
OTHER SO	OURCE	(S):			MAR	PAT	141:	3501	98				-				

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

775286-20-9 CAPLUS

Piperazine, 1-[[2-[((2,6-dichloro-4-fluorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

766558-26-3P, 4-Methoxy-N, 2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl ethyl) benzeneoulfonamide his (trifluoroscotate) 766558-28-5P, 4-Methoxy-N, 2,6-trimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxyl ethyl) benzeneoulfonamide fumariate 775285-56-6P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl ethyl) benzeneoulfonamide difumarate 775285-60-4P, N-[2-[2-[4-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-1-piperazinyl]-2-oxoethoxyl ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzeneoulfonamide fumarate 775285-60-2P, N-[2-[2-[4-(9-Methyl-9-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxyl ethyl-4-methoxy-N-ethyl-2,6-dimethylbenzeneoulfonamide difumarate 775285-76-2P, N-[2-[2-[4-(1-Methyl-9-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxyl ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzeneoulfonamide difumarate 775285-76-2P, N-[2-[2-[4-(1-Hethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl ethyl]-4-methoxy-N, 2,6-trimethylbenzeneoulfonamide fumarate 775285-80-4P, N-[2-[2-[4-(1-Hethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl ethyl]-4-methoxy-N, 2,6-trimethylbenzeneoulfonamide difumarate 775285-90-4P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl ethyl]-4-methoxy-N, 2,6-trimethylbenzeneoulfonamide difumarate 775285-90-7P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl ethyl]-4-methoxy-N-(1-methylethyl)-2,6-dimethylbenzeneoulfonamide difumarate 775285-90-7P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl ethyl]-4-methoxy-N-(2-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl ethyl]-4-dichloro-6-methoxy-N-methylbenzeneoulfonamide fumarate 775285-97-7P, N-[2-[2-[4-(1-Hethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl ethyl]-4-dichloro-6-methoxy-N-methylbenzeneoulfonamide fumarate 775285-97-7P, N-[2-[2-[4-(1-Ehyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl ethyl]-4-methoxy-N-(2-c-trimethylbenzeneoulfonamide fumarate 775286-01-6P, N-[2-[2-[4-(1-Ehyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxyl eth

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

The invention relates to novel heterocyclic benzenesulfonamide compds. I, a method for their preparation, and their therapeutic use and compns.

11

AB The invention relates to novel heterocyclic benzenesulfonamide compds. I, a method for their preparation, and their therapeutic use and compns. [Wherein:

R1. R2, R3, R4 = H, halo, alkyl, alkowy, CF3, or OCF3; Ra = alkyl; Y = saturated C2-5 alkylene optionally interrupted by O, unsatd. C2-4 alkylene, CH2CONHCH2; X = CH or N; p = 2 or 3; A = bond, NH, NNe, (un)branched C1-5 alkylene optionally bearing OH or an owo group; provided that A and X together * N; B = N-containing heterocycle or an amine group optionally substituted by 1 or 2 C1-4 alkyl groups; including salts with acids]. The compds. are useful as analgesics and antiinflammatories, particularly for severe pain. Approx. 150 compds. were prepared For instance, 2,6-dimethyl-4-methoxybenzenesulfonyl chloride was amidated with 2-(methylamino) ethanol, (1004), followed by etherification of the free alc. with tert-Bu bromoacetate (948), deprotection of the tert-Bu ester with TFA (958), and amidation of the resulting acid with 1-(2-(1-pyrrolidinyl)ethyl]piperazine using a resin-bound diimide reagent and NOAT (131), to give invention compound II, isolated as the bis(trifluoroacetate). In a formaldehyde-based biphasic pain response test in mice, one compound gave 438 inhibition of 2nd-phase pain at 3 mg/kg orally, and another gave 40% inhibition at 1 mg/kg orally. In a bradykinin BI receptor assay using human umbilical cord, compds. I had pKB values of 7.5 to 9.2.

17 766558-25-2P, 4-Methoxy-N, 2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxylethyl]-2,6-dichloro-4-fluoro-N-methylbenzenesulfonamide RL: PAC (Pharmacological activityy), RCT (Reactant), SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study), PREP (Preparation); RACT (Reactant or reagent), USES (Uses)

(drug candidate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivos as analgesics and antiinflammatories)

RN 76558-25-2 CAPLUS

CN Piperazine, 1-([2-{(4-methoxy-2,6-dimethylphenyl) sulfonyl] methylamino]eth oxylacetyl]-4-

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate
775286-21-0P, N-[2-12-[4-(1-Methyl-4-piperdidnyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-fluoro-N-methylbenzenesulfonamide
difumarate 775286-22-1P, N-[2-[2-[4-(1-Methyl-4-piperdidnyl)-1piperazinyl]-2-oxoethoxy]ethyl]-4-bromo-2,6-dichloro-Nmethylbenzenesulfonamide 775286-23-2P, N-[2-[2-[4-(1-Methyl-4piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-bromo-2,6-dichloro-Nmethylbenzenesulfonamide difumarate 775286-24-3P,
N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]2,4,6-trichloro-N-methylbenzenesulfonamide 775286-25-4P,
N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]2,4-dichloro-6-methyl-N-methylbenzenesulfonamide difumarate 775286-25-5P,
N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxylethyl]2,4-dichloro-6-methyl-N-methylbenzenesulfonamide 775286-27-6P,
N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxylethyl]2,4-dichloro-6-methyl-N-methylbenzenesulfonamide difumarate
775286-29-P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxylethyl]-2,4dichloro-6-methyl-N-methylbenzenesulfonamide difumarate
775286-29-P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxylethyll-4-piperidinyl)-1-piperazinyl-N-(2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl-N-(2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl-2-oxoethoxylethyllbenzenesulfonamide
difumarate 775287-67-P, 4-Methoxy-N, 2,6-trimethyl-N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl-2-oxoethoxylethyllbenzenesulfonamide
difumarate 775287-67-P, 4-Methoxy-N, 2,6-trimethyl-N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxylethyllbenzenesulfonamide
difumarate 775287-68-P, 4-Methoxy-N, 2,6-trimethyl-N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxylethyllbenzenesulfonamide
RL: PAC (Pharmacological activity) SPN (Synthetic preparation), TRU
(Therapeutic use) BIOL (Biological study), PREP (Preparation)

СМ

766558-25-2 C24 H40 N4 O5 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

766558-28-5 CAPLUS
Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate
(1:1) [9CI) (CA INDEX NAME)

CM 1

CRN 766558-27-4 CMF C26 H42 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-56-8 CAPLUS
Piperazine, 1-{[2-|ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho
xy|acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI)
(CA INDEX NAME)

CM 1

CRN 775285-55-7 CMF C25 H42 N4 O5 S

СМ 2

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN CN

775285-74-0 CAPLUS
Piperazine, 1-[[2-[[4-methoxy-2,6-dimethylphenyl]sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-73-9 CMF C28 H46 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-76-2 CAPLUS
Piperazine, 1-(1-ethyl-4-piperidinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-, (2E)-2-butenedicate (1:1) (9CI) (CA INDEX NAME)

CRN 775285-75-1 CMF C25 H42 N4 O5 S

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-60-4 CAPLUS Fiperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth oxy]acety]-4-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1 -

CRN 775285-59-1 CMF C27 H44 N4 O5 S

CM 2

Double bond geometry as shown.

775285-68-2 CAPLUS
Piperazine, 1-[[2-[ethyl](4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho
xylacetyl)-4-(8-methyl-8-azabicyclo(3.2.1]oct-3-yl}-, (2E)-2-butenedioate
(1:2) (9C1) (CA INDEX NAME)

CRN 775285-67-1 CMF C27 H44 N4 O5 S

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-78-4 CAPLUS
Piperazine, 1-[1-{1,1-dimethylethyl}-4-piperidinyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-77-3 CMF C27 H46 N4 O5 S

CM 2

Double bond geometry as shown.

775285-84-2 CAPLUS
Piperazine, 1-[[2-[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]eth
oxy]acetyl]-4-[1-methyl-4-piperidinyl]-, (2E)-2-butenedioate (1:2) (9Cl)
(CA INDEX NAME)

CM 1

CRN 775285-83-1

2 СЖ

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-89-7 CAPLUS
Piperazine, 1-[(2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)aminojethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-,
(2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-88-6 CMF C26 H44 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-91-1 CAPLUS
Piperazine, 1-{[2-{[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-4-{1-(1-methylethyl)-4-piperidinyl]-, (2E)-2-butenedioate
(1:1) (9CI) (CA INDEX NAME)

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) oxylacetyl-4-(1-ethyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CH 1,

CRN 775285-96-6 CMF C23 H36 C12 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-01-6 CAPLUS Piperazine, 1-{[2-{[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl-4-{1,2,2,6,6-pentamethyl-4-piperidinyl}-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-00-5 CMF C28 H48 N4 O5 S

2 CM

CRN 76-05-1 CMF C2 H F3 O2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

CRN 775285-90-0 CMF C26 H44 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775285-95-5 CAPLUS Piperazine, 1-[[2-[(2,4-dichloro-6-methoxyphenyl]sulfonyl]methylamino|ethoxy|acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

(Continued)

CM 1

CRN 775285-94-4 CMF C22 H34 C12 N4 O5 S

Double bond geometry as shown.

775285-97-7 CAPLUS
Piperazine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]eth

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

775286-05-0 CAPLUS
Piperazine, 1-(8-ethyl-8-azabicyclo[3.2.1]oct-3-y1)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-04-9 CMF C27 H44 N4 O5 S

CM 2

Double bond geometry as shown.

775286-09-4 CAPLUS
Piperazine, 1-{[2-[{4-methoxy-2,6-dimethylphenyl}sulfonyl]methylamino]eth
oxy]acety]-4-{8-(1-methylethyl)-8-azabicyclo[3.2.1]oor-3-yl}-,
(2E)-2-butenedioate (1:2) (9C1) (CA INDEX NAME)

CRN 775286-08-3 CMF C28 H46 N4 O5 S

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN CM 2 (Continued)

Double bond geometry as shown.

775286-21-0 CAPLUS
Piperazine, 1-[[2-[[4,6-dichloro-4-fluorophenyl]sulfonyl]methylamino]etho
xylacstyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9C1)
(CA INDEX NAME)

CM 1

CRN 775286-20-9 CMF C21 H31 C12 F N4 O4 S

CM 2

Double bond geometry as shown.

775286-22-1 CAPLUS
Piperazine, 1-{{2-{{(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino}ethox
y}acetyl}-4-{1-methyl-4-piperidinyl}- (9CI) (CA INDEX NAME)

775286-23-2 CAPLUS
Piperazine, 1-[[2-[[(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino]ethox
ylacetyl]-4-{1-methyl-4-piperidinyl}-, (ZE)-2-butenedicate (1:2) (9CI)
(CA INDEX NAME)

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-26-5 CAPLUS
Piperazine, 1-[[2-[[(2,4-dichloro-6-methylphenyl)sulfonyl]methylamino]etho
xylacetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

775286-27-6 CAPLUS Piperazine, 1-[[2-[[4,4-dichloro-6-methylpheny1]sulfony1]methylamino]etho xylacety1]-4-(1-methyl-4-piperidiny1)-, (2E)-2-butenedicate (1:2) (9C1) (CA INDEX NAME)

CM 1

CRN 775286-26-5 CMF C22 H34 C12 N4 O4 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-28-7 CAPLUS Piperazine, $1-[(2-[(4-methox\dot{y}-2,3,6-trimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)$

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN CM 1

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775286-24-3 CAPLUS
Piperazine, 1-(1-methyl-4-piperidinyl)-4-{(2-{methyl{(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxylacetyl]- (9C1) (CA INDEX NAME)

775286-25-4 CAPLUS
Piperazine, 1-{1-methyl-4-piperidinyl}-4-[{2-[methyl{(2,4,6-trichlorophenyl]sulfonyl]amino]ethoxy]acetyl-, (2E)-2-butenedioate (1:2)
(9C1) (CA INDEX NAME)

CH 1

CRN 775286-24-3 CMF C21 H31 C13 N4 O4 S

СH

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

775286-29-8 CAPLUS
Piperazine, 1-{[2-{[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]methylamino]ethoxylacetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1

CRN 775286-28-7 CMF C25 H42 N4 O5 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

775287-67-7 CAPLUS
Piperazine, 1-[(2-[((4-methoxy-2,6-dimethylphenyl)sulfonyl]methylaminoleth
oxylacetyl]-4-(1-methyl-4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX
NAME)

●2 HC1

775287-68-8 CAPLUS
Piperazine, 1-{[2-{[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (ZE)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1 ,

CRN 766558-25-2 CMF C24 H40 N4 O5 S

СМ 2

Double bond geometry as shown.

775288-70-5P, 4-[4-[[2-[[(4-Methoxy-2,6-dimethylphenyl]]]]]]] methylamino]sthoxylacetyl]-1-piperazinyl]-1-piperidinecarboxylic acid 1,1-dimethylathyl ester
RL: RCT (Reactant) SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of piperazine- and piperidine-containing denzenesulfonamide derivs. as analgesics and antiinflammatories)
75288-70-5 CAPLUS
1-Piperidinecarboxylic acid, 4-[4-[[(2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]sthoxylacetyl]-1-piperazinyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS ON STN ACCESSION NUMBER: 2004:800854 CAPLUS DOCUMENT NUMBER: 141:314016 Preparation of benzenegulfona

INVENTOR(S):

141:314016
Preparation of benzenesulfonamides as Bradykinin Bl receptors antagonists for treatment of pain and inflammation
Barth, Hartine; Bondoux, Hichel; Dodey, Pierre;
Hassardier, Christine; Thomas, Didler; Luccarini, Jean
Hichel

Laboratoires Fournier S.A., Fr. Fr. Demande, 27 pp. CODEN: FRXXBL

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE:

LANGUAGE: FRENCH
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PR:

OTHER SOURCE(S):

		INFOR	na.	Ç14.															
		ENT						DATE			APPI	ICAT	ION	NO.		D.	ATE		
							-									-			
	FR	2852 2852	958			A1		2004	1001		FR 2	2003-	3602			2	0030	325	
	FR	2852	958			B1		2005	0624										
	ΑU	2004	2261	97		A1		2004	1014			2004-							
	CA	2519	110			A 1		2004	1014			2004~							
	WO	2004	0877	00		A1		2004	1014		WO 2	2004-	FR72	3		2.	0040	324	
	WO	2004	0877	00		A8		2004	1118										
		W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
			CN,	CO,	CR.	CU.	CZ,	DE,	DK.	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
			GE,	GH,	GM.	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	
			LK.	LR,	LS.	LT.	LU,	LV.	MA.	MD.	MG.	MK,	MN.	MW.	MX.	MZ.	NA.	NI.	
			NO.	NZ.	OM.	PG.	PH.	PL.	PT.	RO.	RU.	SC,	SD.	SE.	SG.	SK.	SL.	SY.	
												UZ,							
		RW:										SZ,							
												BG,							
												MC,							
			SK.	TR.	BF.	BJ.	CF.	CG.	CI.	CM.	GA.	GN,	GO.	GV.	ML.	MR.	NE.	SN.	
				TG		,	,	,	,	,	,	,	.,	,	,		,	,	
	R.D	1606				A 1		2005	1221		ED 7	2004~	7423	าา		2	חאח	324	
												IT,							
		٨.,										TR,							
	RR	2004	nna s	P Q		Δ.		2006	0328		RD 3	2004-	PERO			2	0040	324	
	m	1764	661	•-		- 7		2006	0426		CN 1	004- 006- 005-	9000	7767		2	0040	324	
	10	2006	5213	าา		Ť		2006	0920		1D 1	2004-	5053	40		2	0040	324	
	MO	2000	0043	61				2006	1101		NO 3	2005-	4361	• •		2	0050	920	
10	DIT	ZOUS Y APP	1 N	INEV OI		^		2005	1101		ED 1	2003-	3501			. 2	0030	326	
		Arr	, and .		• •						FR 6	2003-	4630			n 2	0030	411	
												2004-					0040		
													rn/2	J		n e	~~~~	244	

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

MARPAT 141:314016

AB Title compds. I [wherein R1, R2, R3 = independently H, halo, alky1, alkoxy, CF3, OCF3; Y = CH2CONHCH2, saturated alkylene chain interrupted by O or unsate. A = a bond, (CH2)mm R = saturated N-containing heterocycle selected

from pyrrolidine, morpholine, piperidine, quinuclidine, tropane, or dialkylamino, etc.; X = (CH2)pr m, p = independently 2-3; and their acid addition salts | were prepared as Bradykinin B1 receptor antagonists for

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

REFERENCE COUNT:

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT 10

ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) treatment of pain, inflammation. A 4-step synthesis for benzenesulfonamide II-2TFA is given. Selected I inhibited the second phase of licking response by 40 to 43% in a test of pain induced by formalin in mice. I inhibited Kallidin (a homolog of bradykinn)-induced contraction of isolated human umbilical vein, with e pKB > 7.
765558-26-37, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxosethoxy] ethyl] benzenesulfonamide bistrifluoroacetate 765559-28-57, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo(3.2.1]qct-3-yl)-1-piperazinyl]-2-oxosethoxy[ethyl]benzenesulfonamide fumarate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Uses)
(Bradykinin Bl receptor antagonist; preparation of benzenesulfonamides as Bradykinin Bl receptor antagonists for treatment of pain and inflammation)
766588-26-3 CAPLUS
Piperazine, 1-[(2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy|acetyl]-4-(1-methyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

766558-25-2 C24 H40 N4 O5 S

СМ 2

CRN 76-05-1 CMF C2 H F3 O2

CO2H

766558-28-5 CAPLUS
Piperazine, 1-{[2-{[(4-methoxy-2,6-dimethylphenyl]sulfonyl]methylamino]eth
oxy]acety]-4-{8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate
{1:1} (9C1) (CA INDEX NAME)

CM 1

CRN 766558-27-4 CMF C26 H42 N4 O5 S

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CH 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 186.06 11.48 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -1.56 -1.56

STN INTERNATIONAL LOGOFF AT 10:55:53 ON 10 JUL 2007